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ABSTRACT 
 
The use of metallo-pharmaceuticals, such as the platinum drugs (e.g. cisplatin), for cancer 
treatment illustrates the utility of metal complexes as therapeutic agents. Platinum group 
metal complexes therefore offer potential as anti-tumour agents to fight cancer. Our study 
was aimed at synthesizing and evaluating the effects of palladium(II) and platinum(II) 
complexes as anticancer agents. The synthesis of water soluble pyrazole ligands (L1-L3) 
were performed by means of alkylaminoalkylation reactions. This was achieved by 
reacting either pyrazole or 3,5-dimethylpyrazole with formaldehyde and ethylamine or 
isopropylamine. The reactions were performed in situ. The preparation of the 
corresponding palladium(II) and platinum(II) complexes of L1-L3 were performed by 
reacting the ligands with [PdCl2(NCMe)2] and [K2PtCl4] respectively. The products 
obtained were insoluble in common organic solvents. Another class of compounds (1-5), 
palladium and platinum complexes with pyrazole and pyrazolyl ligands, were synthesized 
directly by using the already available ligands. Palladium complexes, 1, 2, 5, were 
obtained by reacting pyrazole, 3,5-dimethylpyrazole and 3,5-dimethylpyrazolylacetic 
acid ligands with [PdCl2(NCMe)2] while platinum complexes, 3 and 4 were obtained by 
reacting pyrazole, 3,5-dimethylpyrazole with [K2PtCl4]. All compounds were 
characterized by multinuclear NMR, IR, Mass spectroscopy, microanalysis and X-ray 
crystallography in the case of L4.  
 
Compounds 1-5 were then evaluated for their activity as anticancer agents and have been 
discussed in chapter 4. All the cells were cultured in their respective media (e.g. for CHO 
cells, Hams F-12 medium was used) at 37 oC in a humidified 5% CO2 atmosphere for 24 
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h. The compounds to be tested were dissolved in water (or DMSO in some cases) and 
added to media to make a final concentration ranging from 0.02 to 1.00 mM. Cisplatin 
was analysed as the positive control. All experiments were performed for duration of 24 
h. The activity was found to be both dose- and time-dependent. This was achieved by 
performing preliminary analysis of their cytotoxicity on chinese hamster ovary (CHO) 
and normal human fibroblast (NHF) cell-lines using the APOPercentageTM assay with the 
help of Fluorescence Activated Cell Sorter (FACS) techniques. Palladium compounds 1 
and 2 did not show any significant activity on these cell lines while 5 showed activity at 
IC50 value of 0.67 mM after 24 h of treatment. Platinum complexes were more active 
than palladium compounds, with 3 and 4 showing significant activity at IC50 values of 
0.13 and 0.035 mM after 24 h of treatment.  
 
The DNA fragmentation of cells treated with compound 3 and 5 was achieved by 
electrophoresis of the DNA extracted from the treated cells. This was performed on a 2% 
agarose gel at 100V for 1 h and visualized by ethidium bromide staining. The fragments 
of approximately 200 bp observed indicated cell death via apoptosis. Cell cycle studies 
was performed on CHO cells treated with compound 5 (at 0.60 mM), by staining the cells 
with acridine orange (AO) and subsequently evaluating cells FACS techniques. It was 
observed that DNA replication was inhibited at G1- phase with cells (ca. 31%) 
undergoing cell death (via apoptosis) after 24 h. Analysis of interaction of these 
compounds with biomolecules in vitro was achieved by studying the interaction of 
complex 3 and glutathione by 1H NMR spectrum for 24 h at room temperature, indicating 
ligand substitution of the pyrazole ligand by glutathione. 
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Preface 
Many a times, a project of this nature is hard to categorise as to whether it is under 
chemistry, biology, or a combination of all, biochemistry. Thanks to bioinorganic 
chemistry. Bioinorganic chemistry constitutes the discipline at the interface of the more 
classical areas of inorganic chemistry and biology. Although biology is generally 
associated with organic chemistry, inorganic elements are also essential to life processes 
e.g. sodium and potassium as charge carriers in osmotic balance, vanadium in nitrogen 
fixation (oxidase), manganese in photosynthesis among others.  
 
Bioinorganic chemists study inorganic species, with special emphasis on how they 
function in the biological systems, in vivo. Inorganic elements have also been artificially 
introduced into biological systems as probes of structure and function. Metal containing 
compounds have been used not only as biological probes, but also as diagnostic and 
therapeutic pharmaceuticals. The mechanisms of action of platinum anticancer drugs, 
gold antiarthritic agents, and technetium radiopharmaceuticals are some of the currently 
active topics of investigation in bioinorganic chemistry. The potential applications of 
inorganic compounds to improve human health are boundless and therefore this area 
continues to grow rapidly. 
 
Bioinorganic chemistry has two major components: the study of naturally occurring 
inorganic elements in biology and the introduction of metals into biological systems as 
probes and drugs. Peripheral but essential aspects of the discipline include investigations 
of inorganic elements in nutrition, toxicity of inorganic species and ways of overcoming 
them and of course metal ion transport and storage in the body. It is worth noting that 
 xvii
bioinorganic chemistry is extensive and as a consequence, my focus was to evaluate 
palladium and platinum pyrazole and pyrazolyl compounds as anticancer agents.  
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Chapter 1 
GENERAL INTRODUCTION TO APPLICATION OF METALS IN RESEARCH 
FOR ANTICANCER AGENTS 
 
1.1 Introduction 
Medicinal applications of metals can be traced to almost 5000 years back but the lack of 
experience of traditional medicinal chemists and pharmacologists in dealing with 
biologically active metal complexes, poses a substantial activation energy barrier to their 
identifying active metal complexes and shepherding them to the clinic. This factor retards 
the development of metallo-pharmaceuticals. However, it provides enterprising transition 
metal chemists with opportunities to pioneer the development of exciting new drugs.1 
 
Along with an increased understanding of metallo-protein function and some excellent 
models of metal ion active sites, recent advances in understanding how naturally-
occurring metal ions are delivered to these active sites and how metal ions are involved in 
curbing some diseases indicate new roles for metal ions in therapeutic strategies.2 
Although some of the biological functions are also showed by non-metal species e.g. 
tamoxifen and taxol, it is clear that metal ions play a major role in biochemical process. 
Metal ions are known to exert an inductive effect by coordination to the site of reaction 
and serve as redox sites that function by either electron or atom transfer.3 The current 
development of successful metallo-pharmaceuticals, which include the platinum 
anticancer drugs,4 radio-diagnostic agents,5 all indicate the utility of complexes as both 
therapeutic and diagnostic agents. 
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Cancer is one of the diseases that contribute to the high mortality rate globally. Thus 
there has been need for continuous research to develop drugs to curb this disease. Cancer 
is fundamentally a disease at the cellular level, in which cell proliferates indefinitely. 
Consequently, cancer cells continue to grow and divide yielding an ever increasing mass 
referred to as a tumour.6 The tumour grows invasively, destroying surrounding body 
tissues. Cancer cells from this primary tumor may then spread, or metastasize, to other 
parts of the body, where new tumors may begin to grow. Eventually the tumor load will 
cause death, often by physically blocking or compressing blood vessels or organs such as 
the brain. Based on the activities of metal ions in the biological systems as mentioned 
above, development of metal-containing compounds, as therapeutic agents has therefore 
been stimulated and is underway. One of such compounds is cisplatin developed a quarter 
of a century ago. 
 
In the mid 1970s initial antitumour studies with cis-diamminedichloroplatinum(II) 
(cisplatin) indicated considerable activity against some of the cancer cell-lines e.g. 
leukemia L1210 tumours. Cisplatin remains the most effective drug in clinical treatment 
of testicular, ovarian, bladder, head and neck cancers. It is widely used in combination 
with other anticancer drugs such as doxorubicin, and 5-fluorouracil, in treatment of neck 
cancer among others. However, there is an intrinsic and acquired resistance that limits the 
organotropic profile of the drug. Some of the reasons that lead to this acquired resistance 
include; reduced cellular uptake and deactivation of cisplatin by thiol containing 
biomolecules e.g. glutathione.7 
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Nevertheless, today platinum complexes belong to the most promising class of drugs to 
tackle the problem of oncology. A mechanistic understanding of how these metal 
complexes achieve their activities is crucial to their clinical success, as well as to the 
rational design of new compounds with improved potency. However it goes without 
saying that non-metal containing drugs which are considered to be precursors for drug 
development and even as medicines, are still in use even though not easily isolated. The 
next section highlights on some of these organic compounds (natural products) and their 
application in cancer treatment. 
 
1.2 Non-metal containing cancer drugs 
Natural products once served humankind as the source of most drugs, and higher plants 
provided most of these therapeutic agents. At present, natural products, their derivatives 
and analogues are used as remedies and represents over 50% of all drugs in clinical use, 
with higher plant-derived natural products representing approximately 25% of the total.8  
 
In the war on cancer, and through the history of combating the disease of cancer, natural 
products have played an important role in the development of contemporary cancer 
chemotherapy. Between 1960 and 1982 the National Cancer Institute (NCI) screened 
around 114,000 extracts from an estimated 35,000 plant samples for anticancer activity.9 
A major group of these products are the powerful antioxidants, others are phenolic in 
nature, and the remainder includes reactive groups that confer protective properties.10 In 
vitro studies done on these compounds have resulted in a number of clinically useful 
drugs that are now available. Among these clinically useful drugs are paclitaxel (Taxol®) 
vincristine (Oncovin®) 11 podophyllotoxin (a natural product precursor) 12 and 
 4
camptothecin 11, 12 (a natural product precursor for water-soluble derivatives of cancer 
drugs).  
 
Besides natural products that have found direct application as drug entities, e.g. Taxol 
(Fig. 1.1a), there are many others that have served as chemical models or templates for 
the design, synthesis, and semi-synthesis of novel substances for treating diseases some 
of them include (1-pyrenylmethyl)amino alcohol derivatives, 2-amino-1,3-propanediol 13 
and camptothecin (Fig.1.1d). 
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Figure 1.1. Structures of compounds among the clinically useful drugs. a. Taxol, b. 
Vincristine, c. Podophyllotoxin, d. Camptothecin. 
 
 6
 
Although significant progress has been made in cancer chemotherapy, current drugs are 
ineffective against many common cancers (colon, rectum, lung, prostate) 14 and are often 
very toxic. Paclitaxel (Fig. 1.1a) and tamoxifen (Fig. 1.2) are exceptions to ineffective 
drugs.  
 
 
CH3CH2
R
O(CH2)2NMe2  
 
Figure 1.2. Shows the structure of Tamoxifen (R= H) and its derivative 
Hydroytamoxifen (R= OH). 
 
It is worth noting that inorganic based drugs (metal-containing drugs) still remains 
superior to other drugs especially anti-tumour agents. This is for the simple reason that 
whereas for organic drugs fractional guided assays are performed to identify the active 
compound, inorganic compounds are target specific (synthesized with specific design so 
as to bind to the DNA; hence their activity as anti-cancer drugs). In addition, the organic 
compounds are found in smaller quantities in nature and their synthesis in the laboratory 
is very challenging, i.e. it took 12 years to fully synthesise taxol. Even though these 
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drugs, e.g. taxol and tamoxifen, have shown anti-cancer activity, cisplatin is currently the 
most widely used anticancer drug. As a consequence, further research on more effective 
drugs can be achieved by synthesis of other new metal containing compounds.  
1.3 Metal based anticancer drugs (metallo-drugs). 
The development of modern medicinal inorganic chemistry, stimulated by the 
serendipitous discovery of cisplatin, has been facilitated by the inorganic chemist’s 
extensive knowledge of the coordination and redox properties of metal ions. Metal 
centers being positively charged, are favoured to bind to the negatively charged 
biomolecules. The constituents of proteins and nucleic acids offer excellent ligands for 
binding to metal ions. The pharmaceutical use of metal complexes therefore has excellent 
potential that can be exploited.15  
 
Ruthenium and gold complexes with antitumour activity are such examples. Many 
ruthenium complexes with oxidation state 2+ or 3+ display antitumour activity, 
especially against metastatic cancers. Ru(III) complex trans-[Na][Ru(Im)(Me2SO)Cl4]   
(Im = Imidazole) and its analogue, trans-[ImH][Ru(Im)(Me2SO)Cl4], (Fig. 1.3) are 
currently in a clinical trial.16 For ruthenium(III) compounds, in vivo reduction to Ru(II) is 
required for activity. This facilitates its binding to the highly electrostatically charged 
DNA molecule. Cellular uptake of many ruthenium complexes appears to be mediated by 
the iron transport protein transferring process (stimulated by protein transferrin) into the 
tumor cells where upon it is reduced. In general, the cytotoxicity of ruthenium complexes 
and other metals correlates with their ability to bind DNA following intracellular 
activation by their reduction. However other researchers have reported complexes to have 
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shown different mode of action. No conclusive explanation as to its mode of action is 
known but it is reported that it does not involve DNA binding rather it interferes with 
type IV collagenolytic activity and reduce the metastatic potential of the tumors.16  
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Figure  1.3. Structures of trans-[Na][Ru(Im)(Me2SO)Cl4] and trans-
[ImH][Ru(Im)(Me2SO)Cl4]. 
 
Gold complexes on the other hand are mainly known to treat rheumatoid arthritis. 
Surprisingly they have also been reported to show antitumour activity.17 Tetrahedral 
gold(I) complexes with 1,2-bis(diphenylphosphino)ethane and 1,2-
bis(dipyridylphosphino)ethane ligands (Fig 1.4a) display a wide spectrum of antitumour 
activity in vivo, especially in some cisplatin-resistant cell lines. However mechanistic 
studies suggest that, in contrast to cisplatin, DNA is not the primary target of these 
complexes. Rather, their cytotoxicity is mediated by their ability to alter mitochondrial 
function by binding to receptive ligands and inhibit protein synthesis. Very recently, a 
hydrophilic tetrakis-((tris(hydroxy-methyl))phosphine)gold(I) complex (Fig 1.4b) was 
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reported to be cytotoxic to several tumor cell lines e.g. HCT-15 cells, derived from 
human colon carcinoma.18 
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Figure  1.4. Structures of gold(I) complexes. (a) gold(I) complexes with 1,2-
bis(diphenylphosphino)ethane and 1,2-bis(dipyridylphosphino)ethane ligands. (b) 
Tetrakis-(trishydroxymethyl)-phosphine)gold(I) complex. 
 
 
In general much has been done on gold(I) complexes. The logical extension of phosphine 
gold(I) species as reported by Cookson et al. was to couple it to biologically active thiols 
e.g. 6-mercaptopurine and 6-thioguanine.19 It is clear that the presence of the phosphine 
gold(I) entity enhance the potency of the biologically-active thiols. As part of the 
improvement on gold(I) systems, there have been on-going attempts to alter the solubility 
characteristics of phosphine gold(I) thiolates discussed above so as to improve on their 
activity. However, an area of research gaining prominence, with respect to gold 
compounds, based on recent publications, features gold(III) compounds.  
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Gold(III) would normally be regarded as oxidizing, and this property could be 
exacerbated in the reducing mammalian environment. However, judicious choice of 
donor atoms in the ligand donor set can impart stability to the higher oxidation state; 
gold(III) is regarded as an “harder” acid than gold(I) and hence, is more likely to form 
stable compounds with donor atoms such as nitrogen and oxygen whereas gold(I) 
exhibits a distinct preference for sulfur and phosphorous donor atoms. The gold(III) 
compounds investigated for potential anti-tumour activity are inevitably four coordinate 
and feature square planar geometries, as found for cisplatin so that, perhaps, a similar 
mechanism of action, i.e. interaction with DNA and disruption of normal cellular 
processes, may be assumed for these compounds. In this connection, evidence has been 
provided showing that some species bind DNA.20 This fact is supported or related to the 
fact that gold in the +3 oxidation state has the same electronic configuration and 
structural characteristics as the world’s most widely-used anti-cancer drug, cisplatin. 
 
Other significant metal complexes that have been studied are vanadium complexes. 
Although speculation (which has been proven) that these metal complexes may possess 
antitumour activity had existed since the beginning of the 20th century, these complexes 
were not tested until 1967. Since then the chemopreventive and antitumour effects of 
vanadium compounds have been widely investigated, especially on experimental animal 
models and various types of malignant cell-lines e.g. B cell lymphoma, T cell leukemia 
human ovary carcinoma and testicular cancer.21 The first evidence that vanadium may 
exert chemopreventive effects on experimental carcinogenesis was provided by 
Thompson et al. on 1-methyl-1-nitrosurea (MNU-1) -induced mammary carcinogenesis 
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in female Sprague-Dewley rat.22 They then proposed that the chemotherapeutic action of 
vanadium, in biological terms, was found to be mediated through inhibition of altered 
liver cell foci and hepatic nodule growth during the early stages of neoplastic 
transformation as reported elsewhere by Bishaye and co-workers.23 Such compounds are 
the vanadocenes. They are organometallic complexes, with the vanadium(IV) linked to 
organic ligands by direct carbon metal bonds. They have been found to exhibit significant 
antitumour properties both in vitro and in vivo. Like Bis-
(cyclopentadienyl)vanadium(II)chloride, [(η5-C5H5)2VCl2] (Fig. 1.5), which belongs to 
the metallocene class of antitumour agents, has turn out to be one of the most promising 
compounds as a drug among the various non-platinum complexes.  
 
V
Cl
Cl
 
 
Figure 1.5. Bis(cyclopentadienyl)vanadium(II)chloride (vanadocene dichloride). 
 
Vanadocene dichloride has been shown to be a potent antitumour agent against mouse 
tumours and its activity is due to its ability to interact at a molecular level with nucleic 
acids, especially DNA. Furthermore, the antitumor effects of vanadocene dichloride 
against human colon and lung carcinomas were shown to be due to the vanadium 
accumulation in nucleic acid-rich regions and to the inhibition of DNA and RNA 
synthesis in tumor cells,24 suggesting the binding of this compound to the DNA. 
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Rhodium compounds have also been studied extensively. In spite of the fact that these 
compounds are analogous to platinum and ruthenium compounds, their antitumour 
activities have since been reported as insignificant due to their toxic effects.25 However 
dimeric µ-acetato dimers of rhodium(II) as well as monomeric square planar rhodium(I) 
and octahedral rhodium(III) complexes have shown interesting antitumour properties. 
The dirhodium tetraacetate complex, [(CH3COO)4(H2O)2Rh2(II)], (Fig. 1.6) is much 
more inhibitory towards Escherichia coli DNA polymerase I and exhibits good 
antitumour activity against P388 lymphocytic leukemia and sarcoma 180 but little 
activity against L1210 and B16 melanoma.26  
 
Recent structural studies suggest that the antitumour activity of di-rhodium(II) 
carboxylates may bear analogy to that of cisplatin by binding to adjacent guanines on 
DNA.27 Antitumour activity has also been found to increase in the series 
[(RCOO)4(H2O)2Rh2(II)] (R=alkyl group) with the lipophilicity of the R group and is 
independent of its reduction potential.26 Thus rhodium(II) acetate (R = CH3), propionate 
(R = CH3CH2), butyrate (R = CH3CH2CH2), pentanoate (R = CH3CH2CH2CH2) show a 
considerable variation in their antitumour activity against Ehrlich ascites tumour cells in 
mice, with the pentanoate complex being the most active. Lengthening the carboxylate 
alkyl (R) chain beyond the pentanoate was found to reduce the drugs’ therapeutic 
efficacy.  
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Figure  1.6. Six-coordinate cage complex of rhodium(II) carboxylates, 
[(RCOO)4L2Rh2(II)], R = alkyl group, L = H2O or other donor solvent. 
 
1.4 Platinum based anticancer agents. 
Platinum anticancer compounds are currently in widespread use for the treatment of 
many tumors, including genitourinary cancer. This class of interesting chemotherapeutic 
agents arose as a result of experiments performed by Rosenberg in the 1970s. The 
experiments were initially designed to study the effects of electric fields upon the growth 
of bacterium Escherichia coli in ammonium chloride solution over platinum electrodes.28 
To their surprise, they observed an unusual phenomenon of filamentous (long threadlike) 
growth. The bacteria cells, which normally divide rapidly, grew to 300 times their usual 
size and did not divide as expected. This observation was eventually found to result from 
the presence of platinum(II) and platinum(IV) ammine chloride complexes formed in situ 
by electrolysis at the platinum electrodes. 
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   (a) Cisplatin                      (b) Transplatin 
Figure 1.7: Isomeric forms of dichlorodiammineplatinum(II) complex. 
 
Further studies showed one cause of the filamentation to be specifically cis-dichloro-
diamine platinum(II) complex (cisplatin) (Fig. 1.7a). Interestingly this is a classic 
coordination compound, of which the synthesis and its structure had been known for 
more than a century.29 Subsequent investigations of the effects of cisplatin on rapidly 
dividing mammalian tumor cells indicated significant antitumour activity against sarcoma 
180 and leukemia L1210 in mice.30 The relationship between structure and activity was 
found to fulfill the Structure Activity Relationships (SARs) as reported by Kelemu et al.31 
The requirements are: (i) A cis geometry with the general formula cis-[PtX2(amine)2] for 
platinum(II) compounds and cis-[PtY2X2(amine)2] for platinum(IV) compounds. (ii) The 
X ligand should be an anion with intermediate binding strength such as chloride or 
oxalate. In the case of platinum(IV) Y can be chloride, hydroxide, or carboxylate oriented 
trans to each other. (iii) The amine ligands should possess at least one NH moiety 
necessary for hydrogen bonding interactions. 
 
 
 15
Several clinical trials on cisplatin as a drug commenced soon thereafter, and in 1979, it 
was approved by the Food and Drugs Administration (FDA) for the treatment of several 
human cancers. Since then much research attention has been paid not only to cisplatin, 
but also to cisplatin mimics as potential anticancer drugs because of the success of 
cisplatin. Indeed cisplatin, (Fig. 1.7a), one of the most widely used anticancer drugs, is 
effective in treating a variety of cancers, especially testicular cancer.32 As a result, its 
importance in current clinical research towards drug discovery includes emphasis on the 
need to understand its biological chemistry with the ultimate goal of using this 
information to design even more effective drugs.  
 
1.5 Platinum-DNA interactions. 
1.5.1 DNA: The biological cellular target of cisplatin. 
After the discovery of the anticancer properties of cisplatin, work began to investigate its 
mechanism of action. One of the first issues that needed to be settled was its biological 
target, for there are many cellular components that can react with cisplatin e.g. RNA and 
glutathione. Attention has focused on deoxyribonucleic acid (DNA) molecule as the 
generally accepted target and as a consequence many studies have been performed to 
establish the nature of platinum binding to the DNA.33 
 
Through intensive research efforts over the past several years, there is now a fairly 
detailed understanding of how cisplatin and its mimics bind to DNA and how the DNA is 
structurally modified as a result of this interaction.34 One such experiment involved the 
treatment of Escherichia coli bacteria cells with cisplatin, which led to its lysis 
(disintegration), a condition associated with DNA-damaging agents.35 DNA (Fig. 1.8) is a 
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biomolecule and is one of the many cellular components in the human body. It contains 
the complete genetic information that specifies the structure of all proteins and 
ribonucleic acids (RNA). In human cells, there are 46 chromosomes, each consisting of a 
single DNA duplex up to 4 cm long. Each DNA molecule is a polymer of monomeric 
units, the nucleotides, which consists of phosphate group, a 2-deoxyribose sugar, and a 
heterocyclic amine base (Fig.1.9). The deoxyribose sugar and phosphodiester repeating 
units are attached through the sugar moiety to the 9N atoms of adenine, A, and guanine, 
G, (purine bases) or the 1N atoms of cytosine, C, and thymine, T, (pyrimidine bases). 
The ordering of bases from 5’ to 3’ on the DNA strand defines the sequence of that 
particular strand. The sequence of nucleotides is arranged in a helix conformation and 
matches with a complementary one to form a double-helix. The bases point towards the 
centre of the double-helix, and are held together by hydrogen bonds and base stacking, 
while the phosphates are located on the more solvent accessible surface of the helix. In its 
simplicity, the base A pairs with T, and G pairs with C, and the sequence of these base-
pairs determines the genetic coding. 
 
The physical nature of DNA is important to consider due to its fundamental importance 
in metal DNA interactions. The low pKa value of the phosphate groups makes the DNA 
highly charged molecule in a large pH range. As a result, the charge density is high, and 
the DNA attracts oppositely charged ions and repels negatively charged ones. In this 
respect, the nucleobases acts as ligands and thus coordinates to the metal of an already 
positively charged species.31 
 17
 
 
   
  (a)      (b) 
Figure 1.8. DNA structures showing the forms a DNA molecule assume i.e. (a) Helix 
shape together with the (b) hydrogen bonding in the pairing bases.  
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Figure 1.9. Heterocyclic bases of DNA. 
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1.5.2 Effects of platination on structure. 
Based on the cis- and trans-platin complexes, there is need to understand the binding 
modes of these complexes to DNA macromolecule and what effects it has. Both 
complexes are neutral, thermodynamically stable, and known to retain their co-ordination 
environment in circulating blood plasma. The limiting factor for accumulating platinum 
in cells is its concentration. Indeed uptake does not have a pH optimum suggesting that 
the transport is not carrier-mediated.36 These results indicate that cisplatin and its isomers 
enters cells by passive diffusion, although there is some evidence that uptake may in part 
occur by an active transport mechanism.36 In the blood stream (plasma), cisplatin 
encounters a relatively high concentration of chloride ions (ca. 100 mM) that suppresses 
hydrolysis and maintains the compound in a neutral state. Interestingly in the cytoplasm 
of the cell the chloride ion concentration drops to 4 mM (Fig.1.10). The implication here 
is that when the drug (cisplatin) passes through the cell membrane into the cytoplasm, it 
undergoes hydrolysis.  
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Figure 1.10. The cellular uptake of cisplatin and its targets. Reproduced from 
Encyclopedia of Cancer, J. R. Bertino, Ed. Academic Press: San Diego, CA, 1 
(1997) p. 392. 
 
 
This leads to a range of aquated and non-aquated products respectively being formed,37 
[Pt(NH3)2(OH2)2]2+, [Pt(NH3)2(OH)(OH2)]+, [Pt(NH3)2(Cl)(OH2)]+, [Pt(NH3)2(OH)2],  
[Pt(NH3)2(OH)(Cl)] and Pt(NH3)2Cl2. It is the positively charged platinum hydrolysis 
product, [Pt(NH3)2(Cl)(OH2)]+, that is electrostatically attracted by the DNA 
macromolecule. The coordination of these platinum species to DNA is known to occur in 
two steps. Formation of the monofunctional adducts primarily at the N7 position of 
guanine or adenine becomes the first intricate step. This monofunctional platinum-DNA 
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adduct then reacts further to form a bi-functional adduct (Fig. 1.11a, b). This occurs at the 
N7 position of the nearby guanine, and seldomly to the adenine base.38 
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(a)     (b) 
Figure 1.11. Diagram of cisplatin-DNA adducts. (a) depicts an intrastrand crosslink 
and (b) an interstrand crosslink. 
 
Two forms of adduct are seen as a result of this binding. There is the intrastrand cross-
link (Fig 1.11a), whereby the coordinated nucleotide bases are on the same DNA strand 
as opposed to an interstrand cross-link whereby the coordination occurs with the bases 
being on opposite DNA strands as shown in Figure 1.11b above. Normally the products 
are chromatographically separated and identified by their 1H NMR spectra.39 Generally 
48-60% of cis-[Pt (NH3)2{d(GpG)}] and 23-28% of cis-[Pt (NH3)2{d(ApG)}] (d = sugar 
back bond of DNA molecule, A and G are bases as described in section 1.5.1) are found 
as the intrastrand crosslinks.40 The transplatin analogue is stereochemically limited to 
form intrastrands. Nevertheless it has been shown to form kinetically stable adducts with 
DNA via the interstrand binding (Fig. 1.11b), thus indicating that the compound must not 
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necessarily be in a cis conformation (SARs rules) to be active. 1H NMR analysis revealed 
an adduct spectrum of dG-Pt-dC (50%), dG-Pt-dG(40%) and dG-Pt-dA (10%)41 (d = 
sugar back bond of DNA molecule, A, G, C are bases as described in section 1.5.1, 
interstand binding). From these data, it is clear that both cis and trans-type drugs binds to 
DNA through N7 positions of guanine and adenine. The significant difference is that 
stereochemical factor limits trans-type from forming an intrastrand adduct, rather it forms 
interstrand. The type of ligand systems used determines the conformation of the complex 
to be formed. When the ligand is bulky, it favours trans-isomer, although there is a 
mixture of the two isomers in solution. The important thing to note is that they both form 
DNA-platinum adducts, thus inducing cytotoxicity. 
 
However, significant acquired resistance has limited the clinical success of cisplatin. This 
is as a result of the factors mentioned in the previous section. Cisplatin also has large 
dose limiting side effects including signs of nephrotoxicity (kidney damage), 
neurotoxicity (nervous system damage) and ototoxicity (hearing loss). Therefore much 
attention has been focused on designing new second-generation platinum compounds 
with improved pharmacological properties and a broader range of antitumor activity. 
Several platinum complexes are currently in clinical trials.42 Recent work suggests that 
there may be some biologically active trans platinum compounds, including platinum(II) 
complexes with planar ligands,43 platinum(II) iminoether compounds,44 and trans-
ammine(ammine’)platinum(IV) compounds.45 However these new complexes have not 
yet demonstrated significant advantages over cisplatin either in vitro or in vivo. 
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Carboplatin (Fig. 1.12), developed by Johnson Matthey Technology, displays the same 
spectrum of activity against cancer cell-lines as cisplatin.44 There is little or no 
nephrotoxicity and neurotoxicity as the side effects compared to cisplatin. However bone 
marrow toxicity is the known dose-limiting factor. The reduced toxicity is attributed to 
the slow nucleophilic substitution (by water) of the chelated dicarboxylato leaving group, 
with the low reactivity of the complex itself being attributed to its slow ring opening.39 
As a result, carboplatin can be administered at much higher doses (900 mg/m2) than 
cisplatin (60-120 mg/m2). It is worth noting that carboplatin is the only metal containing 
cancer drug, other than cisplatin, to obtain worldwide approval for clinical use to date.46 
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Figure 1.12. Cis-diammine-1,1’-cyclobutane dicarboxylate platinum(II), carboplatin. 
 
Another interesting complex is cis-dichloroamine-2-methylpyridineplatinum(II), 
(popularly known as AMD-473) (Fig. 1.13). It is known to be a sterically hindered 
platinum complex. Crystal structure of the complex has shown that the pyridine ring is 
tilted 102.7o with respect to the PtN2Cl2 square plane.47 The sterically hindered non-
leaving group slows associative substitution reactions on the square planar platinum. This 
is important for biological nucleophiles that are able to bind platinum without prior 
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hydrolysis of the chloro-ligand (e.g. thiol groups of proteins or peptides). AMD-473 
hydrolyses more slowly (two fold) than cisplatin and also shows reduced rates of reaction 
with thiourea and methionine while maintaining reactivity towards DNA.38 
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Figure 1.13. Cis-dichloroamine-2-methylpyridineplatinum(II), AMD-473. 
 
AMD-473 also displays (in vitro) cytotoxicity intermediate between cisplatin and 
carboplatin. In a growth inhibition assay using 11 human ovarian cancer cell-lines, the 
mean concentration that kills 50% of the cells, IC50, of AMD-473 was 8.1 µM, higher 
than the mean for cisplatin (2.6 µM) but lower than the mean for carboplatin (20.3 µM).15 
Its superiority to carboplatin has been attributed to its structure which is a distorted 
square planar geometry and the presence of the aromatic ligand hinders thiol-mediated 
detoxification. It has also been shown to overcome other modes of resistance such as 
reduced cellular uptake and enhanced DNA repair.48 
 
While maintaining the structure activity relationships (SARs) features, another complex, 
trans-L-diaminocyclohexaneoxalatoplatinum(II), oxaliplatin (eloxatin), possessing a rigid 
non leaving group and chelated dicarboxylato as leaving group was synthesized (Fig. 
 24
1.14). The synthesis is based on the fact that having bidentate ligands, which imparts a 
specific stereochemistry to the compound, (cis- conformation) could lead to formation of 
DNA adducts that could not be translabilized or in other words form kinetically stable 
adducts. Oxaliplatin is administered in combination with 5-Fluorouracil plus leucovorin 
(5FU/LV) (these are cancer therapy drugs). It is used to treat patients with colorectal 
cancer (cancer of the colon and rectum) whose disease has recurred or become worse 
following initial therapy with a combination of other drugs.49 It has an improved efficacy 
i.e. it shrinks tumours (in some patients) and delay resumed tumour growth.49 
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Figure 1.14. trans-L-diaminocyclohexaneoxalatoplatinum(II), eloxatin. 
 
1.5.3 Conformational-activity related study. 
There has been a debate concerning the effect of particular compounds being attributed to 
their rigid geometries i.e. cis- and trans- geometry. Young et al. investigated the effects 
of monodentate versus chelate conformation by a direct comparison of 
bis(aceto)amminedichloro(cyclohexylamine)platinum(IV) (a), with its N-cyclohexyl-1,3-
propanediamine analogue (b), (Fig. 1.15).50 Compound a showed selective cytotoxicity 
toward cisplatin-resistant human ovarian tumour cell-lines. The preliminary antitumour 
activity of compound a was found to be inferior to that of b.  
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The variation in their activities may be ascribed to the difference between the 
monodentate amines in the former and the rigid chelating N-cyclohexyl-1,3-
propanediamine (chpda) in the latter. It is possible that the rigid chelating complex forms 
intrastrand specifically, whereas complex exhibiting monodentate character would have 
both isomers, cis- and trans- in solution and would form both intra- and inter-strand 
platinum-DNA adducts; hence its high cytotoxic effect. The chelating effects of neutral 
amine observed both in vitro and in vivo gives a clear indication of the features that can 
be used to control the physicochemical properties of a particular drug during its 
development so as to exhibit desirable biological activity.50 
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Figure  1.15. Monodentate versus chelate amine based complexes. (a) 
Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) and (b) bis(acetateo)-N-
cyclohexyl-1,3-propanediamine platinum(IV). 
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1.6 The kinetics of platinum(II) drugs. 
In an attempt to understand the difference in the activity spectra of the two isomer, cis 
and trans, kinetic studies have been undertaken. As a result, several observations have 
been proposed to explain the difference in the activities of the two isomers. For instance, 
the half-lives of the intermediate platinum-DNA products formed (monofunctional 
adduct), (see section 1.5.2) have been reported to be different for the two isomers. 
Conversion of the monofunctional adduct to a bifunctional adduct is slow for trans-
isomer (30 h) as compared to cis-isomer (15 h). The monofunctional adduct of trans-
isomer would then be susceptible to thiol binding by glutathione (GSH) rendering it not 
to be active.51  
 
Generally it has been found that the rates of reaction of cis- and trans-platin with DNA 
are governed mainly by their rates of hydrolysis. This has been monitored by use of 195Pt-
radiolabelled analogues to investigate the binding reactions directly. The reaction rates of 
both isomers were also found to be the same on double and single stranded DNA, 
implying that local DNA conformation was not a major factor in binding.51 Recent 
studies which employed 195Pt NMR spectroscopy to check the formation of 
monofunctional adducts of cis- and trans-platin and their respective closure to 
bifunctional adducts, gave t½ = 1.9 h and t½ = 2.0 h as respective half-lives for initial 
binding to DNA.52 These values were found to be identical to the half-lives for hydrolysis 
of these compounds. 
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1.7 Interaction of platinum complexes with biomolecules. 
The biomolecules present in blood and cells are varied in their structure and chemical 
reactivity. Many small molecules, proteins and enzymes have the potential to react with 
platinum complexes.53 The sulfur containing molecules can therefore easily coordinate to 
the metal, with sulfur as the binding site to give other forms of metal complexes, which 
leads not only to the inactivity of the drug but also its toxicity in the body system. 
 
The sulfur containing tripeptide glutamylcysteinylglycine, glutathione (GSH), is one such 
example and is the most prevalent sulfur containing molecule in cells. This intracellular 
non-protein thiol is found to have a concentration of up to 8 mM.54 It is known to be one 
of the primary defenses against toxins and oxidants present in the cell. It can deactivate 
electrophilic drugs including chemotherapeutic agents, and is known to scavenge for 
heavy metals in the body. Thus although cellular DNA is considered to be the 
therapeutical target of platinum drugs, a large part of the platinum reacts with cysteine 
groups of proteins instead, which are also constituents of GSH.55 These reactions may 
induce toxic side effects that occur in cancer chemotherapy. More importantly, the 
reaction with these sulfur containing proteins are associated with cellular resistance 
against platinum drugs.56 A lot of studies have been done to this effect. 
 
Hall and co-workers 52 have considered the reaction rates for reduction of platinum(IV) 
complexes versus substitution when reacted with biomolecules.52 Even though none of 
the platinum(IV) compounds that have been put on clinical trial have revealed any 
significantly greater activity in human than of cisplatin and their platinum(IV) analogues 
e.g. carboplatin,57 they found it important in this instance to use platinum(IV) complexes 
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because it was hypothesized that they are activated on reduction by glutathione. Their 
reduction by such biological reductants is in agreement with the assumption that these 
compounds act as pro-drugs to their platinum(II) analogues.58 Hall et al. observed that 
sulfydryl group of glutathione is readily oxidized, with Eo value reported as –240 mV at 
pH 7.0 (close to biological pH).31 
 
   2 GSH  GSSG + 2H+ + 2e- 
 
This was found to be in the range for oxidation by platinum(IV) complexes, which have 
Eo values up to –1000 mV.59 Using trans-[PtCl2(CN)4]2-, Hall and workers also showed 
by using stopped-flow techniques that trans-[PtCl2(CN)4]2- was reduced by glutathione, a 
reaction that proceeded directly without substitution at platinum(IV). The reduction was 
found to be pseudo-first-order, and variation of chloride concentration had no effect on 
the rate of reduction. The rate of reduction was also found to increase with increasing pH, 
suggesting that a deprotonated thiol group is a more reactive species towards 
platinum(IV) complexes.52 
 
The above phenomenon was supported by other research findings, which showed that the 
reaction of tetra-platin with DNA is slow in vitro, but the reaction become rapid upon 
addition of two stoichiometric equivalents of GSH, indicating reduction of the 
platinum(IV) complex to its platinum(II) analogue.60 
      
Pt(IV) + 2 GSH                       Pt(II) + GSSG +2H+ 
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The binding of this biomolecule appears to be irreversible suggesting that a strong bond 
is formed between the central platinum atom of the complex and one or more of such 
molecules.61 This is supported by the fact that platinum complexes, in this case 
platinum(IV), are soft acids and are more likely to form a stable bond with sulfur, a soft 
base. Unfortunately one failure of this study is the fact that it does not clearly indicate the 
reaction at cellular level or when the complex has already penetrated the cell membrane. 
As mentioned earlier, platinum(IV) compounds act as pro-drugs and as a prerequisite 
need to be reduced to platinum(II) before penetrating the cell. In fact structure-activity 
relationship (SAR) rules defined for platinum(II) compounds are significant factors in 
determining the activity of platinum(IV) analogues. While extensive work has been 
carried out on the interaction of platinum(IV) complexes with GSH, very little has been 
reported on its interaction with the platinum(II) analogues. In their attempts, Odenheimer 
and Wolf reacted cisplatin with glutathione in a 1:2 mole ratio respectively.61 They 
postulated possible reaction mechanisms and products for this interaction (Fig. 1.16).  
 
With this in mind, it is then important to investigate the interaction of GSH with 
platinum(II) compounds, because it is actually these compounds that cross the cell 
membrane and react with DNA. Our attempt to do this kind of studies is based on 
pyrazole platinum(II) complexes. 
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Figure 1.16. Representation of possible reaction mechanisms for interaction of cisplatin 
with glutathione 
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1.8. Pyrazole and Nitrogen containing Ligands in synthesis of anticancer agents. 
The properties of metal-coordinated compounds, whether in classical inorganic 
coordination complexes or in organometallic compounds or in bioinorganic compounds, 
are determined in large measure by the nature of ligands bound to the metal ion.62 Most 
ligands are based on nitrogen-containing heterocyclic compounds with exception of a few 
having sulfur and oxygen moieties. The key feature of these heterocycles is their π-
electron deficiency. This is a common feature with bidentate and tridentate nitrogen-
heterocyclic compounds containing 6-membered rings such as 1,10-phenanthroline 
(phen) and 2,2’-bipyridine (bipy). On the other hand, the π-electron excessive five-
membered nitrogen heterocycle, pyrazole is a poorer π-electron acceptor. In fact, it is a 
better π-donor and hence acts as hard donor site. In drug design, especially inorganic 
based, such information is vital.63 
 
The ease of synthesis of variously substituted pyrazoles is the most interesting feature in 
the incorporation of pyrazole groups in the design of new ligands and hence offers the 
opportunity of both electronic and steric control of the properties of the metal complexes. 
Thus pyrazole-based chelating ligands are good in the development of systematic 
coordination chemistry. It is important therefore to have a critical analysis of the 
molecular structural aspects of the resulting complexes. In so doing, understanding 
electronic structural aspects and the reactivity is important. 
 
A new ligand bis[3,5-diisopropylpyrazolyl]ethyl]ether has recently been specifically 
designed 64 to model the binding aspects of zinc to protein backbones in enzymes. (Fig. 
1.17). This demonstrates that the geometries, nuclearities and reactivity properties of a 
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particular compound can be controlled by the change in the coordination mode of 
chelating ligands in the coordination sphere of metal ions; by the placement of substituent 
groups near donor site of a ligand. 
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Figure 1.17. A new ligand, bis-[(3,5-diisopropylpyrazolyl)ethyl] ether 
 
 
Second generation platinum(II) antitumour complexes that carry “non-leaving ligands” 
other than simply ammonia are of interest for their ability to modulate drug metabolism 
and target binding through steric and electronic effects on the substitution mechanism.65 
Several platinum complexes with N-heterocyclic ligands such as imidazole, thiazole, 
benzimidazole, benzoxazole and benzothiazole have been reported, of which some 
showed significant cytotoxicity.66 The use of amines more compatible to the human 
system has been another important area. For this purpose, naturally occurring substances 
like amino acids, peptides, and glucosamines whose uptake is increased in malignant 
cells have been used as non-leaving ligands in some platinum complexes.67 In a study 
performed by Fatma et al., benzimidazole ligands having hydrogen, methyl or amino-
methyl groups at position 2 were used as non-leaving ligands of the platinum(II) 
complexes that they synthesized (Fig.1.18).This was in consideration of three main 
reasons: firstly the sterically hindered ligands were seen to reduce rapid detoxification by 
thiol-containing molecules in the cells. Secondly the use of bidentate ligands such as 2-
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aminomethylbenzimidazole instead of simple ammonia could lead to prevention of 
translabilization and undesired displacement of the non-leaving ligand by sulfur and 
nitrogen donors that are present in the cell. Thirdly, the hydrophobic properties (which is 
one of the important factors) 68 whereby the presence of aminomethyl groups makes the 
ligand water soluble and so (by extension) is the resultant complex. Ultimately the 
solubility of the drug will facilitate drug administration. 
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Figure 1.18. The synthesis of ligands and their complexes. Benzimidazole (Bim), 
Methylbenzimidazole (Mbim) and Aminobenzimidazole (Ambim). Reproduced from 
J. Med. Chem. 38 (2003) 473. 
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Fatma and co-workers observed that complex 2 (Fig.1.18), with the ligands having free 
N-H moiety in the structure, was found to be slightly more active than its corresponding 
methylated derivative, complex 4, to confirm the role of free N-H group of the 
benzimidazole ligands on the cytotoxic activiy of the benzimidazole-platinum(II) 
complexes.68 
 
The coordination environments of metal ions in biomolecules often consist of nitrogen-
donor and oxygen donor atoms, which are provided by histidines and aspartates or 
glutamates. And since pyrazoles resemble imidazoles, it has been incorporated in stable 
chelates to obtain ligand systems applicable in the design of new drugs.69 For example a 
new ligand containing both imidazole and 3,5-dimethylpyrazole moieties (Fig. 1.19) have 
been synthesized which may act as a pentacoordinating ligand.69 
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Figure  1.19. The synthesis of 1,5-bis(3,5-dimethylpyrazol-1-yl)-3-[bis (imidazol-2-yl) 
methyl]-3-pentane (bdpbiap). 
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The methylene chains allow a certain degree of flexibility to the ligand with the 
possibility to form five and six-membered chelate rings. The imidazole group, after loss 
of a proton may form an intramolecular imidazolato-bridge between two metal centers. 
The incorporation of metal ions e.g. palladium(II) and platinum(II) to such ligands (Fig. 
1.19) allows formation of multinuclear complexes. Multinuclear platinum complexes (for 
example) contain two or more linked platinum centers that can each covalently bind to 
DNA, and hence are capable of forming a completely different range of DNA adducts 
compared to cisplatin and its analogues.70 The rationale of the synthesis of this type of 
compounds is the likelihood of facile and selective uptake of the platinum-complexes 
which contain aminoacids/sugars as ligands because these natural products are normally 
taken up by the cell.71 However, to date, there have been no clinically significant 
advances that have been developed from this design approach. 
 
Over the past few years there have been efforts to develop water soluble, nitrogen based 
ligands for synthesis of metallo-drugs. There has been comparatively little attention paid 
to this type of ligands as well. In the limited number of examples published, the 
hydrophilicity has been introduced either through an ionic substituent (cationic or 
anionic) or a polyhydroxy substituent (such as carbohydrate). Sulfonated bipyridine 
ligands (Fig. 1.20A) were among the first examples of nitrogen ligands developed for 
applications in aqueous solution.72  
 
Subsequently, several other monodentate and bidentate ligands either with ionic (Figs. 
1.20B and 1.20C) or polyhydroxy (Fig.1.20D) substituents have been developed. 
Examples of multidentate ligands are the tridentate tris(pyrazolyl)methane (Fig.1.20E) 
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and tris(pyridyl)amine derivatives as well as tetradentate porphyrin ligands.73 In general, 
the subject of nitrogen containing ligands is extensive and cannot be discussed fully; 
however these ligands continue to play a significant role in the design of new drugs. 
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Figure 1.20. Examples of water-soluble nitrogen ligands. 
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1.9 Rationale and Objectives 
Based on the extensive literature given above on the use of metal complexes as anticancer 
agents, it is clear that metal-containing compounds especially cisplatin are important in 
the research towards discovery of better anti-cancer drugs. The widely used ligands and 
complexes are based on imidazole. For instance, several complexes especially platinum 
containing, with N-heterocyclic ligands such imidazole, thiozole, benziimidazole, 
benzoxazole and benzothiozole have been reported. However it is noted that little has 
been done on complexes based on pyrazoles as the ligands. Since pyrazole belong to the 
same class of compounds as imidazole, it is therefore important to try and explore its 
chemistry as far as anti-cancer drugs are concerned.  
 
Pyrazole-type heterocycles thus represent this important class of non-leaving ligands. 
This is because of their rich electronic property that can be altered by appropriate choice 
of substituents on 2-N, 3-C, 4-C, and 5-C atoms of the pyrazole. This in turn enables 
optimization of the electronic property of the metal center. It also boosts the efficiency of 
the drug. For instance, incorporation of aminomethyl groups or carboxylic groups 
improves the solubility of the complexes in water. The presence of the 1H proton in the 
pyrazole ring is ideal for hydrogen bonding in the DNA. In this study, pyrazole and 3,5-
dimethylpyrazole have been used as ligands to synthesise palladium(II) and platinum(II) 
complexes. The choice of palladium as a one of the metals is based on two factors: (i) it 
is an homologue of platinum and thus is expected to show similar activity, (ii) it is cheap. 
The purpose of this research work is therefore to synthesise palladium(II) and 
platinum(II) complexes and evaluate them as anti-cancer agents. 
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Chapter 2 
INTRODUCTION TO BIOCHEMICAL PROCESSES INVOLVED IN CELL 
DEATH 
 
2.1 Introduction to cancer 
Cancer is a disease caused by uncontrolled growth and spreading of abnormal cells. 
Cancer can seriously threaten human health and it is a leading cause of death. Since 1990, 
about 16 million new cancer cases have been diagnosed in the United States, where the 
overall costs for cancer in 2001 were estimated at $156.7 billion. It is estimated that in 
2002 about 1.3 million new cases were diagnosed.1 Although the mechanisms of 
formation and spread of cancer are still not well understood, both external factors (e.g. 
tobacco smoking, chemicals, radiation, and infections) and internal factors (e.g. inherited 
metabolism mutations, hormones, and immune conditions) are believed to be relevant 
causative factors. These may act together or sequentially to initiate and promote 
carcinogenesis.2 
 
Although there have been rapid advances in the development of anticancer drugs, there is 
a lack of proper cure for cancers. A worthy goal at present is to develop treatments that 
produce remission and/or palliation. A cancer is said to be in remission when all clinical 
evidence of cancer has disappeared. It is noteworthy, however, that microscopic foci of 
cancer cells may still remain. Effective treatments include surgery, radiotherapy, 
chemotherapy, hormone-therapy and immunotherapy. Each of these treatment modalities 
has advantages and disadvantages, and their combination is usually needed to produce the 
most effective results.2 
 44
The surgical removal of a cancerous tumor and the surrounding affected tissue is often 
effective and considered as the primary procedure for tumors large enough to manipulate. 
However it is difficult for surgery to be effective and it is usually unavoidable to have 
residual affected cells. In addition, surgery may have the undesirable side effect of 
changing the growth rate of the remaining cancer cells by triggering a faster metastatic 
process. In many cases, patients die of metastatic cancer after the primary tumor has been 
successfully removed.3 Multimodal therapy that utilizes radiotherapy, chemotherapy and 
other forms of treatments to follow surgery provides a better chance to kill the metastatic 
cancer cells or, at least, to keep them in the remission state described earlier. 
 
Thus cancer chemotherapy was first successfully practiced in the 1950s when nitrogen 
mustard, which was used as a war gas, was found to be effective in inhibiting tumor 
growth. Due to extreme toxicity, however, effective chemotherapy with anticancer drugs 
was not widely applied until the 1960s. However in the early 1980s, chemotherapy was 
introduced for treatment of carcinoma with a high expectation of reducing the incidence 
of distant metastases and increasing the possibility of local control. Thus 
chemotherapeutic agents become important as anticancer agents.  
 
2.2 Cytotoxicity 
For many biologists it came as a surprise to realize that the death of a cell is not 
necessarily a bad thing. Actually cell death in metazoans is required for development, 
maintenance and survival of the organism. Physiological cell death has been observed in 
different tissues and in various organisms. Cell death occurs throughout the life span of 
multi-cellular organisms and arguably represents the only irreversible cell fate decision.4  
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Cytotoxicity is the cell-killing property of a chemical compound. Cell death can occur by 
either of two distinct mechanisms, necrosis or apoptosis.5 Necrosis is the pathological 
process, which occurs when cells are exposed to a serious physical or chemical damage, 
whereas apoptosis is the physiological process by which unwanted cells are eliminated 
during development and other normal biological processes.4,5 Loss of viability, whether 
as a result of necrosis or apoptosis, is often defined experimentally as the loss of cell 
membrane integrity. The determination of whether a cell dies by apoptosis as opposed to 
necrosis is best made on the basis of (i) alterations in the cell membrane and cytoplasm 
and (ii) changes in the cells chromatin, both of which occur prior to the lysis (breakdown) 
of the membrane.6 
 
In early stages of apoptosis, changes occur at the plasma membrane. Plasma membrane 
alteration involves the translocation of phosphatidylserine (PS) from the inner side of the 
plasma membrane to the outer layer and is best detected by flow-cytometry.7 The cell 
chromatin condenses and forms aggregates near the nuclear membrane which, in turn 
becomes convoluted, whilst the nucleolus becomes enlarged and appears abnormally 
granular (Fig. 2.1).8 It is generally assumed that these morphological changes result from 
a developmental programme for cell death that can be triggered by deprivation of a 
growth factor, or by addition of a xenobiotic compound such as cancer therapeutic drug. 
In addition, apoptosis involves the fragmentation of the genomic DNA, an irreversible 
event that commits the cell to die and occurs before changes in plasma membrane 
permeability. This DNA fragmentation has been shown to result from activation of 
endogenous Ca2+ and Mg2+ -dependent nuclear endonuclease. This enzyme selectively 
cleaves DNA at sites located between nucleosomal units (linker DNA) generating mono- 
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and oligonucleosomal DNA fragments. It occurs in a predictable pattern in which the cell 
nucleus becomes condensed; the cell itself shrivels forming small apoptotic bodies. They 
are engulfed and digested i.e. phagocytosis. Other key elements signifying apoptosis 
includes protease cascade and mitochondrial changes.6  
 
 
Figure 2.1. Apoptotic programmed cell death. Reproduced from Apoptosis and Cell 
Proliferation, 2nd Ed. 1998, Germany, p.2. 
 
In vivo, these apoptotic bodies are rapidly recognized and phagocytized by either 
macrophages or adjacent epithelial cells.4 As a result of this, no inflammatory response is 
elicited on the adjacent cells, in contrast to necrosis whereby the cellular contents are 
released into the extracellular fluid thereby causing inflammation, and hence triggering 
the release of chemokines and cytokines which then activates the inflammatory response 
of the nearby cells. 
 
To the extent that most traditional anticancer chemotherapy drugs exert their cytotoxic 
effects by inducing apoptosis, apoptosis-modulating drugs for treating cancer have been 
available for many years.9 However, these agents initially act nonspecifically by either 
damaging DNA or disrupting the cytoskeleton, and do so in both tumor and normal cells. 
 47
As a result of this apoptosis research in cancer drug discovery is paramount in that we not 
only synthesize new drugs, but we also probe them for their ability to kill the tumours 
without side effects on the neighbouring cells.10 Metallo-drugs fortunately have been 
found to induce apoptosis. Two complexes of the type trans-
[PtCl2(isopropylamine)(amine’)] evaluated by Perez and coworkers (Fig 2.2), showed 
apoptotic activity on Pam 212-ras murine keratinocytes cells.11  
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Figure 2.2. Structures of (a) trans-[PtCl2(isopropylamine)(dimethylamine)], (b) trans-
[PtCl2(isopropylamine)(butylamine)] which have shown apoptotic activity (reference 
herein). J. Inorg. Biochem. 77 (1999) 37. 
 
This paves way for more research to be done on cisplatin analogues. Of interest is the fact 
that there is the expectation that elucidation of the cellular mechanisms that lead to 
apoptosis may allow this form of cell death to be included more effectively by cancer 
therapeutic agents.12 In addition, the apoptotic mechanism of cell death is fundamental to 
the normal development of tissues and organisms, in contrast to cell death by necrosis 
which is usually accidental and therefore do not have such significance but is primarily 
pathological. 
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2.3 Apoptosis 
2.3.1 Cell membrane alteration. 
Apoptosis is a distinct form of cell death that proceeds along a genetically determined 
execution programme. It exhibits a characteristic morphology i.e. shrinking of cells (Fig. 
2.1). There are other unique biochemical alterations that lead to this process. One such 
process is the alteration of the cell membrane. The cell membrane is described as a semi-
fluid mosaic structure composed of phospholipids with a diverse group of inserted 
proteins and some cholesterol. The phospholipids in the membrane are arranged in the 
form of a ‘bi-layer’ i.e. an asymmetric membrane in composition, structure and function. 
(Fig. 2.3). 
 
 
Figure 2.3. The asymmetric phospholipids composition of a transformed mammalian 
cell. Reproduced from APOPercentage Assay Manual, 2nd Ed. Ireland, 2002, p.10. 
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The outer leaflet of the lipid membrane is composed of choline containing phospholipids, 
(phosphatidylcholine and sphingomyelin), that is in contact with the extra-cellular matrix,  
(in vivo), or with cell culture medium, (in vitro). The inner leaflet of the membrane is 
composed of phosphatidylethanolamine and phosphatidylserine and is in contact with the 
cell’s cytoplasm. The non-polar, hydrophobic fatty acid tails of the phospholipids of both 
leaflets make up the interior volume of the membrane, giving the typical bi-layer 
structure, as seen by electron microscopy. 
 
The asymmetric composition of the membrane phospholipids is essential in maintaining a 
viable cell. The membrane and its components selectively control the exchange of 
molecules and the generation of concentration gradients between the cytoplasm and the 
extra cellular fluid. To ensure normal trans-membrane functions the phospholipids must 
be maintained in an asymmetric distribution. The process is regulated by ‘flippases’ that 
catalyse the active transport of aminophospholipids from the outer to inner monolayer.13 
In cells undergoing apoptosis, flippase is counteracted by the action of another enzyme 
known as ‘floppase’.14 The net effect of floppase action is the scrambling of the 
phospholipid distribution between the inner and outer monolayers, better known as the 
flip-flop mechanism. The flipping of phosphatidylserine molecules to the surface of the 
membrane permits the transport of a dye into the cell (as shown in the Fig. 2.3) allowing 
it to accumulate within the cell. This is a biochemical alteration that is unique with cells 
dying by apoptosis, and by extension allows the investigation of the cell death 
mechanism by monitoring and quantifying the dye uptake. 
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Figure 2.4. Analysis of cells dying apoptotically using a fluorescence-activated cell 
sorter.  
 
The above figure shows typical results obtained for both the untreated and the treated 
cells respectively. The fluorescence-activated cell sorter is used to make measurements 
on individual cells. The cells that take up dye become fluorescent, and thus the intensity 
of fluorescence observed is directly proportional to the amount of cell death in a given 
population of cells. The cells in category M1 are regarded as normal cells and M2 as 
apoptotic cells. The Forward Scatter and the Side Scatter plots (FSC, SSC) of the treated 
cells shows that they have condensed (shrunk) while the untreated cells have maintained 
their morphology. 
 
2.3.2 Cell-cycle and its interruption 
Apart from the anticancer agents binding to the DNA hence its activity, there are many 
other processes that culminate to the demise of the treated cells, e.g. cell division 
interruption. Cell division is responsible for DNA replication.15 It is important to try and 
Results Acquisition
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understand what these chemical agents do at a cellular level, i.e. disrupting the cell cycle 
which regulates cell division and multiplication concurrently.  
 
Cells reproduce by duplicating their contents and then dividing into two. This happens by 
means of cell division.4 It is principally the way by which all living things are 
propagated. The cell cycle is an ordered set of events, involving cell growth and division 
into two daughter cells. In unicellular species, such as bacteria, each cell division 
produces an additional organism whereas in multicellular species many rounds of cell-
division are required to not only make new individuals but also to replace cells that are 
damaged.16 The vast majority of cells doubles their mass and duplicates all their 
cytoplasmic organelles in each cell-cycle. Thus there is a set of cytoplasmic and nuclear 
processes to be coordinated with one another during the cell cycle and this is achieved 
through a cell-cycle control system that coordinates the cycle as a whole.5 
 
The cell cycle is divided into several distinct phases, of which the most dramatic is 
mitosis, the process of nuclear division, which precedes to cell division itself. In mitosis 
the chromosomes condense into visible structures. In addition, the cells microtubules are 
reorganized to form the mitotic spindle that will eventually separate the chromosomes.17 
As mitosis proceeds, the cell seems to pause briefly in a state called metaphase, in which 
the chromosomes, already duplicated, are aligned on the mitotic spindle, poised for 
segregation.18 The separation of the duplicated chromosomes marks the beginning of 
anaphase, during which the chromosomes move to the poles of the spindle, where they 
de-condense and reform intact nuclei. The cell is then pinched into two (daughter cells) 
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by a process called cytokinesis, which marks the end of mitosis better referred to as M 
phase.15 
 
    
Figure 2.5. The four phases of a standard eukaryotic cell cycle culminating in cell 
division. Reproduced from Molecular Biology of the Cell, 3rd Ed. Garland Publishing, 
Inc. New York and London, p. 863. 
 
 
The much longer period that elapses between one M phase and the next is known as 
interphase. By microscopy the cell appears to be in a dormant phase which is a deceptive 
observation as other techniques have revealed that it is a stage during which elaborate 
preparations for cell division takes place in an orderly sequence i.e. the DNA in the 
nucleus is replicated. DNA replication occurs in a small portion of interphase called the S 
phase (S for synthesis).19 The interval between the completion of M phase and beginning 
of S phase is called the G1 phase (G for gap) whereas the interval between the end of 
DNA synthesis and the beginning of mitosis is called the G2 phase. G1 is known to 
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regulate and control the cell cycle. During G1 the cell monitors its environment and its 
own size and when ready, it takes a decisive step that commits it to DNA replication and 
completion of a division cycle. The G2 phase provides a safety gap, allowing the cell to 
ensure that DNA replication is complete before getting into mitosis. However if the cells 
in G1 phase do not encounter DNA replication, they pause their progress in the cycle and 
subsequently enter a special resting state which is referred to as G0 phase indefinitely. 
Other research scientists in this field have regarded this phase as a phase entered by 
apoptotic cells. 
 
2.3.2.1 Simultaneous identification of G0- and apoptotic cells by DNA and RNA 
content measurement. 
In this kind of study, there is a need to reveal whether a particular agent or treatment 
administered may preferentially induce apoptosis of G1- or G0-cells in cell populations 
which consist of a mixture of cycling and quiescent G0-cells.20 During apoptosis as 
described earlier, calcium and magnesium-dependent nucleases are activated and as a 
result degrade the DNA. This means that within the DNA there will be nicks and breaks 
leading to its fragmentation. This can always be detected using a number of techniques 
which include: - using strand break labelling (TUNEL) technique to detect broken DNA, 
using Hoechst binding to detect DNA conformational changes, and DNA analysis by 
looking at a sub-G1 peak.  
 
The sub-G1 peak analysis is one of the widely used techniques in determination of 
apoptosis. Cell dying apoptotically, undergo chromatin condensation and degradation of 
the genomic DNA respectively. The sub-G1 method relies on the fact that after DNA 
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fragmentation there are small fragments (low molecular weight DNA) and therefore 
when cells are permeabilized, these fragments leak out in the subsequent rinsing and 
quantitative staining procedure. As a result, the cells that have lost DNA will take up less 
of the DNA-binding dye and thus the resultant Ap-peak appearing to the left of the G1 
peak (Fig. 2.6). 
 
 
   
 
Figure 2.6. Cell cycle statistical histogram showing the apoptotic cells appearing at the 
left of G1 peak. 
 
The advantage of this method is that it is very rapid and will detect cumulative apoptosis 
and is applicable to all cell types. However, in order to be seen in the sub-G1 area a cell 
must have lost enough DNA to appear there; so for example if cells enter apoptosis from 
the S or G2/M phase of the cell-cycle or if there is an aneuploid population undergoing 
apoptosis, they may not appear in the sub-G1 peak. In conjunction with the above 
information, simultaneous measurement of cellular DNA and RNA can be done. This is 
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one of the sub-G1 peak types of analysis. It has been shown that 90% of the cellular RNA 
is the rRNA. In this context the G0-cells (apoptotic) are known to contain a 5-10 fold 
lower rRNA content compared with their proliferating (growing) counterparts.21 Thus 
flow cytometry measurement of cellular RNA content enables quiescent cells to be 
distinguished from cycling cells.21 
 
The use of acridine orange, which has metachromatic properties, enables this type of 
analysis to be performed. At an appropriate concentration and ionic conditions, this dye 
intercalates into DNA and fluoresces green, whereas the product of its interaction with 
RNA fluoresces red. Thus cells with lower DNA staining than that of G1-cells (Sub-G1 
peak) are considered apoptotic.22 
 
2.3.3 DNA fragmentation 
Apoptosis as described earlier is morphologically characterized by early cell shrinkage, 
and chromatin condensation, among other changes. The nuclear fragmentation of such 
cells is one of the more extensively studied biochemical events in apoptosis. DNA 
double-strand cleavage occurs in the linker regions between nucleosomes, and produces 
DNA fragments that are multiples of approximately 185 base pairs (bp).23 These DNA 
fragments can readily be detected by agarose gel electrophoresis. DNA fragmentation has 
long been used in distinguishing apoptosis from necrosis and is among the most reliable 
methods of detecting apoptotic cells. In pure cell populations, biochemical changes in 
chromatin and eventually DNA degradation provide useful and often quantifiable means 
of detecting apoptosis. In contrast, cells that undergo necrosis are normally accompanied 
by random DNA breakdown, and therefore exhibit diffuse smears in the agarose gel 
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instead of clear ladders. Nevertheless classical biochemical methods, such as gel 
electrophoresis, indicate the difference in DNA degradation content of the cells which 
have undergone apoptosis as opposed to necrosis. In apoptosis there is presence of 
oligonucleosome-sized fragments of DNA, which when analysed on agarose gels, 
produce ‘ladders’ (Fig. 2.7) whilst necrosis does not.  
 
DNA fragmentation during apoptosis is considered to occur in two stages. Walker et al. 24 
reported sequential degradation of genomic DNA, initially to high molecular weight 
DNA fragments of approximately 300 kb, followed by the appearance of 50 kb loop-size 
chromatin fragments which are detected using pulse-field gel electrophoresis. 
Oligonucleosomal DNA fragments that produce the characteristic 200 bp DNA ladder are 
released when the 50 kb fragments are further degraded. 
 
Figure 2.7. DNA fragmentation pattern. DNA laddering profile showing separation of 
DNA fragments of different sizes by using different concentrations of agarose gel in 
electrophoresis. Higher concentrations of agarose facilitate separation of small DNAs, 
while low agarose concentrations allow resolution of larger DNAs.  
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2.3.4. p53, mitochondria, caspases, and other DNA damage responses in apoptosis 
The definition of p53 is a nuclear protein that functions as a transcription factor capable 
of regulating genes.25 It plays a central role in the coupling of cell damage to cell cycle 
arrest and hence induction of apoptosis. In response to cellular stress exerted by hypoxia 
or the presence of DNA damage, the cellular p53 level increases and p53 is activated by 
modification26 and turns on the transcription of its target genes.25 The p53 cell cycle 
arrest pathways involve p21 gene (WAF1, CIP-1) and Growth Arrest and DNA damage-
inducible gene, GADD45. The p21 is a cyclin-dependent-kinase (cdk) inhibitor. It binds 
to a number of cyclin-cdk complexes and proliferating cell nuclear antigen (PCNA) to 
block cell cycle progression in G1 and G2. GADD45 also binds to PCNA and arrests the 
cell cycle in G2.26 
 
The decision whether an individual cell undergoes growth arrest or apoptosis following 
p53 activation, appears to depend on a variety of factors, such as environmental 
conditions and the cell type. Depending on the cell type, augmentation of insulin like 
growth factor binding protein 3 (IGF-BP3) and Bax expression contribute to apoptosis 
induction by p53.27 Bax, a mammalian cell death protein that targets mitochondrial 
membranes, binds to and thereby antagonizes Bcl-2 (anti-apoptotic protein) and probably 
facilitates cytochrome c release by forming pores into mitochondria membrane.28 In the 
context of cellular DNA damage following p53 cell cycle arrest, some control mechanism 
evaluates whether the DNA can be repaired in a reasonable time or whether the damage 
is severe and hence the cell undergoes apoptosis in a p53 dependent manner.29 
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Caspases, a set of cysteine proteases that are activated specifically in apoptotic cells, are 
known to possess an active-site cysteine, and cleave substrates at Asp-Xxx bonds (i.e. 
after aspartic acid residues). Caspase is thought to be central component that triggers 
apoptotic pathway because of the visible changes it causes that suggests cell death via 
apoptosis. These enzymes participate in a cascade that is triggered in response to pro-
apoptotic signals and culminates in cleavage of a set of proteins, resulting in the 
disassembly of the cell. Most of the morphological changes observed have been reported 
to be caused by a set of cysteine proteases that are activated specifically in apoptotic 
cells.30 
 
One role of caspases is to inactivate proteins that protect living cells from undergoing 
apoptosis. For example, experiments performed by Nagata and co-workers 31 showed that 
the caspase-activated deoxyribonuclease (CAD), responsible for DNA fragmentation pre-
exists in living cells as an inactive complex with an inhibitory sub-unit, called ICAD. The 
cleavage of CAD-ICAD complex i.e. activation of CAD, occurs by means of caspase-3-
mediated cleavage of the inhibitory sub-unit (ICAD) hence fragmentation of DNA and 
apoptosis respectively.31 Many other caspase substrates have been reported over years but 
the commonly discussed are caspases-2, 3, 7, 8, 9, and 10. Other negative regulators of 
apoptosis cleaved by caspases include, Bcl-2 proteins and nuclear lamins,32 focal 
adhesion kinase (FAK) and p21-activated kinase 2 (PAK2).33 
 
 
 59
Mitochondria play an essential in eukaryotic life and death. It is the power house of a cell 
but also plays a critical role in the control of apoptosis regulation. In fact a variety of key 
events in apoptosis focus on mitochondria, including the release of caspase activators e.g. 
cytochrome c, changes in electron transport, loss of mitochondrial trans-membrane 
potential, altered cellular oxidation-reduction, and participation of pro- and anti-apoptotic 
Bcl-2 family proteins. The different signals that converge on mitochondria to trigger or 
inhibit these events and their down-stream effects delineate several major pathways in 
physiological cell death.34 It is understood that the effectors of apoptosis are represented 
by a family of intracellular cysteine proteases known as caspases. Inhibiting caspases, 
however, does not always inhibit cell death induced by pro-apoptotic stimuli. Although 
caspase inhibitors block some or all of the apoptotic morphology induced by growth 
factor withdrawal, achromycin, ultraviolet (UV) radiation, staurosporine or 
glucocorticoids, they do not necessarily maintain replicate or clonogenic potential; 
ultimately, the cells die despite inactivation of caspases.35 In addition, some pro-apoptotic 
proteins such as Bax, induce mitochondrial damage and cell death when caspases are 
inactivated. Such experimental observations support the fact that a caspase-independent 
mechanism of death exists. This mechanism is found to involve mitochondria.36 
 
The importance of mitochondria in apoptosis was suggested by studies with a cell free 
system in which, spontaneous, Bcl-2-inhibitable nuclear condensation and DNA 
fragmentation were found to be dependent on the presence of mitochondria.37 
Subsequently, another study showed that induction of caspase activation by addition of 
deoxyadenosine triphosphate depended on the presence of cytochrome c released from 
mitochondria during extract preparation. During apoptosis (in vitro and in vivo) 
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cytochrome c is released from mitochondria and this is inhibited by the presence of Bcl-2 
on the organelles. Cytosolic cytochrome c then forms an essential part of the vertebrate 
‘apoptosome’ which is composed of cytochrome c, Apaf-1, and pro-caspase-9.36 The 
result is activation of caspase-9, which then processes and activates other caspases and 
leads to cell death. Other apoptosis mediators released from mitochondria include pro-
caspase-3 that is liberated into the cytosol during apoptosis and apoptosis inducing factor 
(AIF) which processes purified pro-caspase-3 in vitro. In general all these factors include 
the pathways and mechanisms involved in apoptosis when cells are treated with 
compounds being investigated.  
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Chapter 3 
SYNTHESIS OF PYRAZOLE LIGANDS AND THEIR COMPLEXATION WITH 
LATE TRANSITION METALS 
 
3.1 Introduction 
Cis-dichlorodiammineplatinum(II) complex (cisplatin), is one of the most effective drugs 
in clinical treatment of testicular, ovarian, bladder, head and neck cancers. However there 
are factors that limits it organotropic profile as a drug. That includes both the intrinsic 
and acquired resistances to the drug by patients. It has several side effects that include 
nephrotoxicity and neurotoxicity.1 
 
Due to these reasons, there is a lot of research in the design of other drugs; platinum 
based (including other metals, i.e. palladium) anticancer complexes which posses 
improved clinical efficacy.2 Hence the reason why second-generation platinum(II) 
antitumour complexes that carry non-leaving ligands other than simply ammonia are of 
interest for their ability to modulate drug metabolism and target binding through steric 
and electronic effects on the substitution mechanism. 
 
In this study pyrazole and its derivatives were chosen as the non-leaving ligands of the 
palladium(II) and platinum(II) complexes in consideration of three main reasons. The 
sterically hindering ligands may reduce rapid detoxification by thiol-containing 
molecules and that the hydrophobic properties of the ligands taken into consideration.1 
The early SARs have defined the necessity of at least one NH moiety which is believed to 
be important for H-bonding interaction towards DNA.3 While maintaining these factors, 
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the incorporation of aminomethyl groups at position 4 of the pyrazoles was adopted to 
afford an ideal ligand for synthesis of water soluble complexes. In this chapter we report 
the synthesis of this type of ligands together with attempts of their complexation. The 
preliminary in vitro antitumour activity of the complexes tested on mammalian CHO cell-
lines is reported in chapter 4. 
 
3.2 Experimental 
3.2.1 Materials and methods. 
All chemicals and other reagents other than those described were used as received.  
[PdCl2(NCMe)2] was prepared according to the literature methods.4 All the palladium and 
platinum complexes used in this study were also synthesized as per literature procedures 
4,5 and their characterization have just been reported (not discussed) to show the purity of 
the compounds. Glutathione used in some of the experiments performed was purchased 
from Acros Organics. The water used was double distilled. All manipulations of air-
and/or moisture sensitive compounds were performed under a dry, deoxygenated nitrogen 
atmosphere using Schlenk techniques. IR spectra were recorded as NaCl cells on a 
Perkin-Elmer, paragon 1000 PC FTIR spectrophotometer. 1H NMR spectra were 
recorded on a Gemini 2000 instrument in CDCl3 and DMSO-d6 solution at room 
temperature (200 MHz). 1H chemical shifts were referenced to the residual signals of the 
protons of the solvents and are quoted in ppm. GC-MS was recorded in the electron 
impact mode, EI at 70 eV on a Finnigan-Matt GCQ equipped with 30 m HP-SMS 
capillary column with a stationary phase based on (5%-phenyl)-methylpolsiloxane. 
Elemental analysis was performed on a Carlo Erba NA analyzer in the department of 
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chemistry, University of the Western Cape and on a Fisons analyzer in the department of 
chemistry, University of Capetown.  
 
3.2.2 Crystallographic structure determination 
Crystal evaluation and data collection were performed on a Bruker CCD-1000 
diffractometer with Mo Kα (λ = 0.71073 Å) radiation and the diffractometer to crystal 
distance of 4.8 cm. The initial cell constants were obtained from three series of ω scans at 
different starting angles. The reflections were successfully indexed by an automated 
indexing routine built in the SMART program. These highly redundant datasets were 
corrected for Lorentz and polarization effects. The absorption correction was based on 
fitting a function to the empirical transmission surface as sampled by multiple equivalent 
measurements. A successful solution by the direct methods provided all non-hydrogen 
atoms from the E-map. All non-hydrogen atoms were refined with anisotropic 
displacement coefficients. All hydrogen atoms were included in the structure factor 
calculation at idealized positions and were allowed to ride on the neighboring atoms with 
relative isotropic displacement coefficients.  
 
3.2.3 Synthesis of Ligands 
3.2.3.1.  3,5-dimethyl-4-(ethylamino)methylpyrazole  (L1) 
A mixture of 3,5-dimethylpyrazole (1.00 g, 10.4 mmol), paraformaldehyde (0.48 g, 16 
mmol), KOH (0.9 g, 16 mmol) and ethylamine (2 ml, 20 mmol) were dissolved in 50 ml 
of water. The mixture was kept under reflux conditions for ca. 51 h. The product was 
extracted from the aqueous solution using CHCl3 (2 x 60 ml) and dried with anhydrous 
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MgSO4 for one minute. The solids were separated by filtration and the colourless filtrate 
concentrated to dryness in vacuo. The product was isolated as oil. Yield = 1.25 g (78%).  
IR (Nujol): 3250 (υN-H), 2970 (υC-H), 1589 cm-1 (υC-N). 1H NMR (CDCl3): δ 4.62 (br, 1H, 
NHEt), 3.53 (br s, 2H, CH2NHEt), 2.81 (q, 3JHH = 7.4 Hz, 2H, NCH2CH3), 2.21 (s, 6H, 
CH3), 1.07 (t, 3JHH = 7.4 Hz 3H, NCH2CH3). 13C{1H}NMR (CDCl3): δ 143.6 (C(CH3)), 
114.2 (C(CH2NHEt)), 44.3 (CH2NHEt), 39.8 (CH2CH3), 17.2 (CH2CH3), 10.1 (C(CH3)). 
 
3.2.3.2.  4-isopropylaminopyrazole (L2) 
Pyrazole (1.00 g, 14.70 mmol), paraformaldehyde (0.67 g, 11.35 mmol) and KOH (0.9 g, 
16 mmol) were transferred to a Schlenk tube, dissolved in 50 ml of water and stirred for 2 
min. before adding isopropylamine (1.88 ml, 43.24 mmol).The reaction mixture was kept 
under reflux conditions for 4 days. The product was then extracted as in 3.2.3.1 above. 
Yield: 1.12 g (71%) 1H NMR (CDCl3): δ 7.59 (s, 1H, 5-Pz); 6.33 (s, 1H, 3-Pz); 4.99 (br s, 
2H, CH2NHi-Pr), 3.67 (br, 1H, NHi-Pr), 2.65 (m, 1H NCH(CH3)2), 1.04 (d, 6H, 
NCH(CH3)2). Anal. Calc. for C7H13 N3: C, 60.40; H, 9.41; N, 30.19%. Found: C, 59.95; 
H, 9.28; N, 29.62%. 
 
3.2.3.3.  3,5-dimethyl-4-(isopropylamino)methylpyrazole  (L3). 
A mixture of 3,5-dimethylpyrazole (1.00 g, 10.4 mmol), paraformaldehyde (0.48 g, 16 
mmol), KOH (0.9 g, 16 mmol) and isopropylamine (1.3 g, 20 mmol) were dissolved in 50 
ml of water and refluxed for 48 h. Extraction was done as in 3.2.3.1 above. The product 
was isolated as clear oil. Yield = 1.53 g (87%). IR (Nujol): 3272 (υN-H), 2962 (υC-H), 
1571cm-1 (υC-N). 1H NMR (CDCl3): δ 4.80 (br, 1H, NHi-Pr), 3.53 (br s, 2H, CH2NHi-Pr), 
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2.81 (m, 1H, NCH(CH3)2), 2.04 (s, 6H, CH3), 1.06 (d, 3JHH = 5.8 Hz, 6H, NCH(CH3)2). 
13C{1H}NMR (CDCl3): δ 144.8 (C(CH3)), 113.2 (C(CH2NHi-Pr)), 48.3 (CH(CH3)2), 39.2 
(CH2NHi-Pr), 20.2 (CH(CH3)2), 11.1 (C(CH3)). MS, EI (70 eV); m/z 167 [1]+. Anal. 
Calc. for C9H17 N3: C, 64.63; H, 10.25; N, 25.12%. Found: C, 62.18; H, 10.46; N, 
23.03%. 
 
3.2.3.4.  Synthesis of 1N-triphenylchloromethane-3,5-dimethylpyrazole.(L4) 
3,5-dimethylpyrazole (1.00 g, 10.4 mmol) was transferred to a Schlenk tube. 
Triphenylchloromethane (2.90 g, 10.4 mmol) was also transferred to the same Schlenk 
tube. Toluene (40 ml) and triethylamine (2 ml) was added respectively and the solution 
degassed with N2 gas for about 1 min. The solution was stirred under reflux conditions at 
80 oC overnight. The salt was then filtered and the solvent evaporated to obtain a brown 
solid as the product. Chromatography was performed to purify the product with 
CH2Cl2:Hexane (5:1 ratio). The product crystallized upon slow evaporation of the solvent 
to give X-ray quality crystals. Yield: 2.57 g (73%) IR (Nujol): 1701 cm-1 (υC=C) 1571cm-1 
(υC-N). 1H NMR (CDCl3) δ 7.45, 7.143 (15 H, (C6H5)3); 6.03 (s, 1H, 4-Pz); 2.23 (s, 3H, 5-
Me); 1.46 (s, 3H, 3-Me). 
 
3.2.4 Synthesis of complexes 
3.2.4.1 Bis-(3,5-dimethyl-4-(ethylamino) methylpyrazole)pallladium(II)  (C1) 
3,5-dimethyl-4-(ethylamino)methylpyrazole (0.12 g, 0.77 mmol) was dissolved in about 
3 ml of dichloromethane in a Shlenck tube. Then 0.1 g (0.385 mmol) of [PdCl2(NCMe)2] 
was dissolved in dichloromethane (20 ml) and transferred to the same Schlenk tube. The 
reaction mixture was degassed and stirred at room temperature for a period of 6 h. to 
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obtain the product as an insoluble precipitate in dichloromethane. Yield: 0.14 g (75%) IR 
(Nujol): 3349 cm-1 (νN-H), 1701 cm-1 (υC=C) 1566cm-1 (νC=N). Anal. Calc. for C16H30 
N6PdCl2: C, 36.90; H, 5.75; N, 18.44%. Found: C, 37.81; H, 5.90; N, 15.05%. 
 
3.2.4.2 Attempted synthesis of palladium and platinum complexes of ligands L2 and L3 
Attempts to synthesise these complexes were performed. Unfortunately full 
characterization of the compounds obtained could not be performed as most of the 
reactions produced insoluble solids e.g. reaction C1 above. 
 
3.3. Spectroscopic data of the complexes used 
3.3.1 Cis-dichloro-bis-(pyrazole)palladium(II) (1). 
1H-NMR (CDCl3): δ 11.69 (br s, 2H, N-H); 8.12 (s, 2H, 5-Pz); 7.59 (s, 2H, 3-Pz); 6.38 (s, 
2H, 4-Pz). IR (Nujol): 3299 cm-1 (νN-H), 1500cm-1 (νC=N). Anal. Calc. for C6H8 N4 Pd Cl2: 
C, 22.99; H, 2.57; N, 17.87%. Found: C, 23.59; H, 2.15; N, 17.78%. 
 
3.3.2 Cis-dichloro-bis-(3,5-dimethylpyrazole)palladium(II) (2). 
1H-NMR (CDCl3): δ 11.83 (br s, 2H, N-H); 5.70 (s, 2H, 4-Pz); 2.67 (s, 6H, 5-Me); 1.92 
(s, 6H, 3-Me). IR(Nujol): 3188 cm-1 (νN-H), 1568 cm-1(νC=N). Anal. Calc. for 
C10H16N4PdCl2: C, 32.50; H, 4.36; N, 15.16%. Found: C, 33.47; H, 4.50; N, 15.26%. 
 
3.3.3 Cis-dichloro-bis-(pyrazole)platinum(II) (3). 
1H NMR (CDCl3): δ 7.93 (d, 2H, 5-Pz, 2JHH = 2.2Hz); 7.48 (d, 2H, 3-Pz); 6.40 (s, 2H, 4-
Pz). IR (Nujol): 3217 cm-1 (υN-H), 1520 cm-1 (υC-N). Anal. Calc. for C6H8 N4 Pt Cl2: C, 
17.92; H, 2.01; N, 13.93%. Found: C, 18.31; H, 1.34; N, 13.84%. 
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3.3.4 Cis-dichloro-bis-(3,5-dimethylpyrazole)platinum(II) (4). 
1H NMR (CDCl3): δ 12.08 (br s, 2H, N-H); 5.75 (s, 2H, 4-Pz); 2.37 (s, 6H, 5-Me); 2.12 
(s, 6H, 3-Me). IR (Nujol): 3210 cm-1 (υN-H), 1568 cm-1 (υC-N). Anal. Calc. for 
C10H16N4PtCl2: C, 26.20; H, 3.52; N, 12.23%. Found: C, 26.70; H, 3.16; N, 12.13%. 
 
3.3.5 Dichloro-bis-((3,5-dimethylpyrazolyl)acetic acid )palladium(II) (5) 
1H NMR (DMSO-d6): δ 2.31 (s, 6H, CH3, pz); 2.42 (s, 6H, CH3, pz); 5.61 (s, H, CH); 
6.04 (s, 2H, pz). IR (Nujol): 1756 cm-1 (υC=O), 3410 cm-1 (υO-H). Anal. Calc. 
C12H16N4O2PdCl2.0.5CH2Cl2; C, 32.25; H, 3.23; N, 12.04 %. Found. C, 32.27; H, 3.41; N, 
12.25 %. 
 
3.6 Results and discussions 
Compounds L1 – L3 were synthesized according to equation 1 below by reacting the 
appropriate pyrazole with formaldehyde and an appropriate secondary amine (either 
isopropylamine or ethylamine). 
N N
RR
N N
R R
(i) HCHO 
(ii) R'NH2
KOHaq / Reflux
H
H
N
R'
H
R' = iPr, Me.  R = H, Me   (1) 
 
The pyrazole ligands e.g. L3, were prepared by alkylaminoalkylation of the 
dimethylpyrazole (eq.1). The formaldehyde-amine mixture under reflux conditions leads 
to aminomethylation of pyrazole at position 4 resulting in thermodynamically stable 
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product of the reaction. The product is isolated as an oil. These ligands were found to be 
soluble in dichloromethane. 1H NMR spectrum of the ligand is a spectroscopic evidence 
of the formation of the new pyrazole. The missing peak at 5.72 ppm of the starting 
material, 3,5 dimethylpyrazole, confirms substitution in position 4 of the pyrazole. 
Further presence of CH2NHR signals at 3.53 ppm supports.  
 
Figure 3.1. 1H NMR of 3,5-dimethyl-4-(isopropylamino)methylpyrazole (L3) 
 
Infrared Spectroscopy was a useful technique in further characterization of the ligands. 
As most of these ligands were oils, recording of spectra was performed on the neat oil 
between NaCl plates. For ligand L3 the most important stretching frequencies to note are 
the v(N-H) (in the aromatic ring) and v(N-H+ C-H) (in the alkyl chain) (eq. 1) which 
appeared at 3272 and 2962 cm-1 respectively. The latter frequency confirms the 
incorporation of the alkylamino chain in position 4 of the parent pyrazole. The stretching 
frequencies found at 1571 and 1710 cm-1  correspond to v(C=C) and v(C=N) respectively. 
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The v(C=C) is a strong sharp band as opposed to v(C=N) which in this case is moderate 
though more than often is variable. 
 
The gas chromatography coupled with Mass Spectrophotometer (GC-MS) was run to 
investigate the purity and subsequently obtain the fragmentation pattern of the ligands. 
The gas chromatograph (GC trace) of L3 obtained, indicated 80% purity of the ligand 
(Fig. 3.2). The mass spectrum of ligand L3, obtained from the Mass Spectrometry 
component of the GC-MS, showed molecular ion peak at m/z: =167[HL]+ with a base 
peak at m/z =109 (Fig. 3.3) along with other pyrazole fragments.  
 
 
Figure 3.2 Mass spectrum of ligand, L3. This is a typical GC trace obtained for pure 
compounds. 
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Fragmentation patterns of the ligands were obtained by mass spectrometry which is 
coupled with GC component as mentioned above. Normally the mass spectral 
fragmentation of the compound is found to give a characteristic pattern. Each kind of 
fragment has a particular ratio of mass to charge, or m/z value. For most ions, the charge 
is 1, so that m/z is simply the mass of the fragment. Thus for ligand L3 it exhibited a 
systematic fragmentation pattern (Scheme 1). It gave a molecular ion peak of m/z =167 
with a corresponding base peak (the most intense peak signifying a stable fragment) of 
m/z =109. This corresponds with a methyl-substituted heterocycles that looses a H to 
produce the corresponding tropylium ions, which are frequently the base peak. Ethyl and 
higher substituted heterocycles will undergo β-cleavage, losing alkyl and producing a 
tropylium ion.7 The fragmentation of the heterocycle rings, which includes pyrazole ring, 
is as a result of small and stable, neutral molecules, which are analogous to HCN, such as 
C=NH as well as HC CH and thus is not discussed herein. 
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Figure 3.3. Mass spectrum of L3. 
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Scheme 1. Fragmentation pattern of L3. 
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The pyrazole ligand L4 was prepared by reacting the two starting material. The product 
isolated was a brown solid. It is very soluble in organic solvents e.g. dichloromethane. 
These were efforts to establish another synthetic route other than the in situ synthesis that 
was used. Our hypothesis was that, with the new route we would improve both the yields 
and purity. This was also to avoid the possibility of obtaining side reaction product i.e. 
3,5-dimethyl-1-(isopropylamino)methylpyrazole instead of 3,5-dimethyl-4-
(isopropylamino)methylpyrazole, which was the desired product. This was achieved by 
protecting position 1 of the parent pyrazole with triphenylchloromethane (eq. 2). The 1H 
NMR spectrum of the ligand gave an indication of the formation of the new ligand. The 
peaks at δ 2.23 and 1.45 ppm (Fig. 3.4) shows that as opposed to the 3,5-
dimethylpyrazole parent ligand where protons of both methyl groups resonate at same 
frequency, those of the new ligand synthesized resonate at different frequency suggesting 
different chemical environments. 
N N
Cl
H
+
Toluene
-Et3NH+Cl-
N N
 
(2) 
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Figure. 3.4. 1 H NMR spectrum of 1N-triphenylchloromethane-3,5-dimethylpyrazole. 
 
Infrared spectroscopy of L4 revealed the stretching frequencies of the functional groups 
present together with those of the phenyl rings. They were found at 1701 cm-1 for v(C=N) 
and 1550 cm-1 for v(C=C). The stretching frequencies of the protons in the phenyl rings, 
v(C-H) were significant at 2800-3000 cm-1 accompanied by the strong bending 
frequencies at 696-886 cm-1. Of interest was the absence of v(N-H) frequency at ca. 3200 
cm-1 suggesting full derivatization of the parent pyrazole. 
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Figure 3.5. IR spectrum of L4. 
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Figure. 3.6. One possible fragmentation pattern of L4. 
 
The fragmentation pattern of ligand L4 was obtained in the same way as described for 
L3. It exhibited a molecular ion peak at m/z = 338 and base peak at m/z = 165. The 
fragmentation pattern involved the loss of a benzene ring first with a subsequent loss of 
the other two rings as shown in (Fig. 3.6). This showed that the attachment of the phenyl 
rings to the pyrazole through a tertiary carbon is not that stable. However it is observed 
that the fragment having two phenyl rings attached to a carbon with an m/z value of 165 
(Fig 3.6) becomes the stable fragment in agreement with the fact that the phenyl rings are 
the metastable ions of the ligand.7 
 
Attempts to use ligand L4 to obtain compound L3 as an alternative route were 
unsuccessful as there was an immediate formation of suspension, which was not the 
desired product. This was attributed to the disintegration of L4 back to its starting 
material due to the reaction being performed under reflux conditions (100oC) which 
surpassed its conditions of synthesis (80oC). 
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3.7 Molecular structure of L3 
Single crystals of the above mentioned ligand suitable for X-ray structural analysis were 
obtained from recrystallization of the ligand from dichloromethane and hexane at room 
temperature. The molecular structure, ORTEP, of the ligand is shown in Figure 3.7. 
Crystal data, together with the data collection and refinement parameters are presented in 
Table 3.1. Selected bond lengths and angles are given in Table 3.2. 
 
Figure 3.7. Molecular structure of compound L4. 
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Table 3.1. Crystal data and structure refinement for L4 
 
Empirical formula  C24 H22 N2 
Formula weight  338.44 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 9.5264(5) Å α = 90°. 
 b = 8.6992(4) Å β = 93.961(1)°. 
 c = 21.9714(11) Å γ = 90°. 
Volume 1816.47(16) Å3 
Z 4 
Density (calculated) 1.238 Mg/m3 
Absorption coefficient 0.072 mm-1 
F(000) 720 
Crystal size 0.41 x 0.27 x 0.19 mm3 
Theta range for data collection 2.14 to 26.39°. 
Index ranges -11<=h<=11, -10<=k<=10, -27<=l<=27 
Reflections collected 14683 
Independent reflections 3708 [R(int) = 0.0392] 
Completeness to theta = 26.39° 99.8 %  
Absorption correction Multi-scan with SADABS  
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Max. and min. transmission 0.9864 and 0.9709 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3708 / 0 / 237 
Goodness-of-fit on F2 1.031 
Final R indices [I>2sigma(I)] R1 = 0.0349, wR2 = 0.0906 
R indices (all data) R1 = 0.0420, wR2 = 0.0950 
Largest diff. peak and hole 0.293 and -0.244 e.Å-3 
 
 
 
Table 3.2. Selected bond lengths [Å] and angles [°] for L4 
 
Bond lengths [Å] 
  
N(1)- C(2)  1.3673(14) 
N(1)- N(2)  1.3690(13) 
N(1)- C(6)  1.4950(13) 
N(2)- C(4)  1.3299(15) 
C(1)-C(2) 1.4914(17) 
C(6)-C(7)  1.5425(15) 
C(6)-C(13)  1.5430(14) 
C(6)-C(19)  1.5472(15) 
C(7)- C(12)  1.3948(16) 
Bond angles [o] 
N(1)-C(6)-C(7) 110.07(8) 
N(1)-C(6)-C(13) 106.17(8) 
N(1)-C(6)-C(19) 109.44(8) 
N(2)-N(1)-C(6) 120.34(9) 
C(2)-N(1)-N(2) 111.75(9) 
C(2)-N(1)-C(6) 127.80(9) 
C(7)-C(6)-C(19) 107.23(8) 
C(13)-C(6)-C(19) 110.91(8) 
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The molecular geometry around the achiral carbon (C6) is tetrahedral. 3,5-
dimethylpyrazole and phenyl groups in this compound, posses a delocalized π –system 
with the preferred ring being the parent pyrazole. In this case the structure is found to 
belong to Td group because of the identical phenyl rings not residing in the same plane as 
the parent pyrazole, leading to the steric repulsions being minimized. The bond angles 
between the substituents to the achiral carbon were found to be 107.23(8)o and 110.91(8)o 
for C(7)-C(6)-C(19) and C(13)-C(6)-C(19) respectively. The bond angles of N(1)-C(6)-
C(19), N(1)-C(6)-C(13) and N(1)-C(6)-C(7) were found to be 109.44(8) o, 106.17(8) o and 
110.07(8) o suggesting a slight distortion of its geometry from conventional angle of 
109.5 o.8 The presence of phenyl rings imparts some steric hindrance and hence leading to 
that slight distortion of the geometry. This again shows that the more bulky the molecule, 
the further its geometry distortion. The bond distances, N(1)-C(2), N(1)-N(2), and N(2)-
C(4) were found to be 1.3673(14) Å, 1.3690(13) Å and 1.3299(15) Å respectively and are 
not significantly different from those reported by LIamas et al.9 which are in the range of 
1.3450(20)-1.3230(30) Å The other bond distances C(6)-C(7), C(6)-C(13) and C(6)-
C(19) were found to be between 1.5425(15) Å and 1.5472(15) Å but longer than N(1)-
C(6) (1.4950(13) Å) suggesting that the phenyl rings were further away from the parent 
pyrazole. The C=N bond, N(2)- C(4), was found to be shorter than C-N bond, N(1)- C(2), 
by 0.0374 Å signifying that the bond strength involved in the former is higher. 
 
The synthesis of palladium(II) and platinum(II) complexes using ligands L1-L3 
performed. However most of the resulting complexes turned out to be insoluble in most 
common solvents and therefore could not be characterized fully. The IR data revealed 
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stretching frequencies at 3349, 1712 and 1666 cm-1 corresponding to v(N=H), v(C=C) and 
v(C=N) respectively. The microanalysis data obtained for C1 were found to be slightly 
higher than expected with percentage calculated carbon content, C being 36.90 while 
found was 37.81. Nevertheless these data were found to be within reasonable values for 
the proposed formula of ML2X2. However it must be pointed out that these data is not 
conclusive. 
 
The Figures 3.8-3.10 below shows the typical 1H NMR and IR spectra of the complexes, 
1–5, that were investigated for their biological activity. 
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Figure 3.8. 1H NMR spectrum of compound 1. 
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Figure 3.9. 1H NMR spectrum of compound 2. 
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Figure 3.10. IR spectrum of compound 1. 
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3.8 Conclusion 
Ligands L1,-L3 were prepared as per the reported methods and obtained in high yields, 
between 71-87%. In all instances they were isolated as clear oils. Attempts to use 
compound L4 as a starting material in the synthesis of L2 and L3 were unsuccessful. 
This is attributed to the instability of L4 at higher temperatures as synthesis of the former 
two ligands involved high temperature reflux conditions. All these compounds were 
characterized by a combination of analytical techniques, 1H and 13C NMR spectroscopy, 
Infrared (IR) spectroscopy, together with microanalysis in some cases. They were all 
found to be soluble in polar solvents, especially chlorinated organic solvents. 
 
Despite these type of ligands having been used to synthesise pyrazolate rhodium(I) 
complexes as reported by Gloria et al.10, our efforts to synthesis the palladium and 
platinum analogues with a target of obtaining square planar, water soluble complexes 
were futile as the products obtained were insoluble solid products (yellowish in colour) 
and therefore could not be fully characterized. We could only postulate that the desired 
complexes were formed. However, it must be pointed out that the microanalysis data 
found were higher than expected in some cases. Nevertheless other palladium and 
platinum complexes, 1-5, were successfully synthesized and fully characterized. They 
were obtained in moderate yields. The dichloropalladium complexes were soluble in 
common chlorinated organic solvents while dichloroplatinum complexes were soluble 
mostly in DMSO. 
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Chapter 4 
EVALUATION OF PALLADIUM AND PLATINUM COMPLEXES AS 
ANTICANCER AGENTS AND OTHER EXPERIMENTS. 
 
4.1 Introduction 
Since the discovery of the anticancer activity of cisplatin several new platinum 
complexes have been synthesized and tested for biological activity. Although the precise 
mechanism underlying antitumour action of platinum drugs is not completely understood, 
they are known to bind to DNA primarily by forming bifunctional adducts.1 Currently 
there are a number of successful metallopharmaceuticals, which include carboplatin and 
iproplatin, for cancer treatment, indicating the utility of metal complexes as therapeutic 
agents. The potential antitumour activity of platinum group metal complexes is well 
understood. However, some tumours are resistant to treatment with cisplatin, thus there is 
a need to develop novel metal containing drugs, to treat this disease. 
 
In an attempt to broaden the medical applications of such compounds, five complexes, 
containing either palladium or platinum, were investigated preliminarily for their activity 
in chinese hamster ovary (CHO) and normal human fibroblast (NHF) cell-lines. The 
morphological changes observed 24 h after treatment of CHO and NHF cells with the 
compounds showed that the treated cells reduced in volume significantly without 
membrane breakage. Further bio-assay performed on CHO cells indicated that the effect 
was both dose and time dependent.  
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4.2 Biological tests 
4.2.1 Cell culture and drug treatment 
CHO, NHF, MG, Hela and Jurkat cell-lines were used in the study. The CHO cells were 
cultured in Hams F-12 medium containing, L-glutamine, 5% foetal calf serum (FCS) and 
0.2% v/v streptomycin-penicillin at 37 oC in a humidified 5% CO2 atmosphere.2 The 
exponentially growing cells were harvested from a 25 cm2 culture flask by means of 
trypsinisation and the cells were recovered by centrifugation. The cell pellet was re-
suspended in Hams F-12 medium and the resulting cell suspension seeded at a cell 
density of 2.5 x 104 cells per well in 6- well tissue culture plates and incubated for 24 h at 
the above conditions. Compounds to be tested were dissolved in water (or DMSO in 
some cases) and added to media to make a final concentration ranging from 0.02 to 1 
mM. In all instances, cells supplied with media i.e. without compounds was used as the 
negative control (untreated cells) while cells treated with cis-
dichlorodiammineplatinum(II) complex (cisplatin) were analysed as the positive control. 
Reaction of some complexes with glutathione (GSH) was achieved by mixing the 
(reactants) in a stoichiometric ratio of 1:2, (Pt(II):GSH) as reported in the literature3 with 
DMSO-d6 as the solvent. 
 
4.2.2 Evaluation of cell death and apoptosis 
In most instances the treated cells were incubated for 24 h except for the time-course 
experiments. In the case of time course experiments, the cells were treated for different 
times, i.e. 0, 6, 12, and 24 h. The cells were then washed twice afterwards using PBS 
(phosphate buffered saline) and the cells stained for 1 h using APOPercentageTM dye 
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according to the supplier’s instruction. The effect of the compounds on the cells (dose 
response), and the dye up-take by the cells were evaluated by both light microscopy and 
Fluorescence Activated Cell Sorting (FACS) techniques. 
 
4.2.3 Evaluation of cell cycle arrest using acridine orange 
The cells were treated and incubated as described in the above sections. After washing 
with PBS, the cells were trypsinised. The cells were centrifuged to obtain a pellet, which 
was then re-suspended in media. Then 0.1 mL of the cells in suspension were stained 
using acridine orange according to the suppliers’ instruction. The cells were evaluated 
within 30 min. of staining using FACS techniques.  
 
4.2.4 DNA fragmentation 
For DNA fragmentation analysis, 2.5 x 104 cell/mL were plated in six well plates. The 
cells were exposed to various concentrations of compounds 3 and 5 for 24 h. After 
treatment the cells were harvested by trypsinisation. The DNA was extracted using 
reported literature protocol.4 The DNA was electrophoresed on a 2% agarose gel at 100 V 
for 1 h. The DNA was visualized by ethidium bromide staining and photographed under 
UV illumination. 
 
4.3 Dichloro-bis-(pyrazole)platinum(II)-glutathione, 1:2 reaction 
Complex 3 (0.010 g, 0.025 mmol) was transferred to an NMR tube and dissolved upon 
addition of DMSO-d6 (0.500 ml) giving a clear yellowish solution. Glutathione (0.015 g, 
0.050 mmol) was then added to this solution. Immediately there was a formation of 
suspension which disappeared with time to leave a clear yellowish solution. The reaction 
was monitored over a period of 18 h by 1H NMR spectroscopy. 
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4.4 Results and discussion 
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Scheme 4.1. Structures of compounds 1-5 that have been evaluated for their apoptotic 
activity. 
 
4.4.1 Morphological changes 
CHO and NHF cells were exposed to various concentrations of the compounds 1-5 being 
investigated (section 4.2.1). The morphological changes observed showed that there was 
a reduction in size i.e. cell volume of the treated cells over a period of 24 h (Fig. 4.1). In 
addition, the decrease in cell volume was accompanied by a loss of contact with 
neighbouring cells as the apoptotic cells shrank and became detached from the adjacent 
cells. Upon staining with APOPercentage dye, the treated cells exhibited dye uptake 
while the negative controls (untreated cells) did not. This is a characteristic feature shown 
by cells dying via apoptosis. This observation is supported by the fact that cells 
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undergoing apoptosis, have their phoshatidylserine (PS) translocated by the enzyme 
flippase leading to its expression externally.5 As a result, the PS trans-membrane 
movement as proposed by ‘flip-flop’ mechanism results in the uptake of the dye.  
 
 
  
A      B 
 
  
C      D 
Figure 4.1. The morphological effects exerted by complexes on CHO and NHF cells 
respectively 24 h after treatment. Photographs were taken (before staining) using a Nikon 
inverted light microscope (20X Objective). A and C shows the untreated cells (CHO and 
NHF respectively) while B and D shows cells treated with 0.5 mM of compound 3 and 1 
mM of compound 5 respectively. 
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In addition, the visible cell shrinkage observed was due to the net movement of fluid out 
of the cell as a result of inhibition of Na-K-Cl coupled transporter system which controls 
the cell volume by maintaining the osmotic balance inside and outside the cells at all 
times6 (see Figures 4.1 and 4.2). 
   E      F 
 
  
 
 
 
G      H 
 
Figure 4.2. Photographs of treated and untreated CHO cells, APOP dye staining. The 
photographs show morphological effects exerted by complexes on CHO cells 24 h after 
treatment with complex 3 (0.5 mM). E and F show untreated and treated cells before 
staining while G and H show the untreated and treated (same) cells after staining. Only 
the treated cells stained positive with APOP dye (H). 
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4.4.2 Concentration effect on the cell death, dose response 
The preliminary antiproliferative activity of the palladium(II) and platinum(II) complexes 
synthesized were determined on CHO cell-line. The cells were incubated for 24 h with 
various concentrations of the compounds, ranging from 0 to 1 mM and using cisplatin as 
the reference. Five complexes were screened for their cytotoxicity on CHO cells, and 
evaluated for whether or not their cytotoxicity was by apoptosis (programmed cell death). 
The percentage of cell death due to the treatment with these complexes was evaluated in 
terms of APOPercentageTM dye uptake by the cells using FACS analysis (Fig. 4.3). 
 
From the observation made, complexes 3, 4 and 5 induced apoptosis significantly. In all 
the cases, drug treatment in the concentration range between 0 and 1 mM resulted in a 
dose dependent inhibition of the cell survival (Fig. 4.4). From the IC50 (concentration of 
compound needed to inhibit cell growth by 50% against a single cell line) values obtained 
(Table 4.1), it clearly indicated that platinum compounds were more effective compared 
to palladium compounds. Complex 3 and 4 showed activity at IC50 of 0.120 and 0.035 
mM respectively. Complex 5 induced a 50% decrease in cell population (IC50) at 0.67 
mM while the other two palladium compounds 1 and 2 showed no significant activity 
(Fig. 4.6). At 0.05 mM, complex 3 were found to induce apoptosis to a percentage of 
approximately 26% while complex 5 induced a cell death of up to ca. 22% at 0.5 mM. 
The difference here is attributed to the nature of the metal used. In this case platinum 
containing compound 3 was more active than the palladium containing compound 5 as 
mentioned above. 
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Figure 4.3. FACS Analysis. Typical acquisition histograms obtained by FACS when 
quantifying the amount of live and dead cells. Cells in M1 are live cells while those in 
M2 are dead cells. Complex 3 was administered to the CHO cells for 24 h. The cells were 
washed with PBS and stained with APOP dye for 1 h as described in the text. The above 
histograms show concentration dependence of the cell death. 
 
Untreated cells 
Treated cells (0.05 mM) 
Treated cells (0.10 mM) 
Treated cells (0.15 mM) 
Treated cells (0.20 mM) 
Treated cells (0.50 mM) 
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Figure 4.4. Graphical representation of concentration-dependent effect of the compounds 
3, 4, and 5 on the treated CHO cells (24 h) respectively. The data was obtained by 
performing APOPercentageTM assay. The graphs show that increase in concentration of 
the compounds being tested causes an increase in cell death (by apoptosis). 
 
Table 4.1. IC50 values (mM) for the complexes tested in CHO cells (n.d. not detected) 
Complex IC50 
1 n.d 
2 n.d 
3 0.12 
4 0.035 
5 0.67 
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The same observation was made when the activities of 2 and 4 were compared. The two 
complexes have the same ligand, 3,5-dimethylpyrazole, coordinated in a monodentate 
fashion but to different metals. Complex 4 induced a significant cell death of 57% at 0.5 
mM compared to 2 which did not induce any significant cell death at the same 
concentration. This again serves to show the superiority of platinum complexes over 
palladium complexes. Despite palladium and platinum being elements of the same group 
and that their ionic radii are nearly the same as a result of lanthanoid contraction, their 
respective pyrazolic complexes exhibited varied activities with platinum compounds 
showing higher activity than palladium compounds. This observation is attributed to the 
associative substitution mechanism of the respective complexes suggesting that their 
kinetic behaviour is quite different even though they show similar coordinative 
behaviour.7 Thus palladium complexes are less kinetically stable and as a result could 
undergo translabilization and undesired displacement of the non-leaving ligand by other 
nitrogen donors easily (especially those coordinated in a monodentate fashion) whereas 
platinum compounds are known to be kinetically inert. This implies that palladium 
compounds are not stable and therefore in the cellular environment will be translabilized 
easily by other biomolecules such as GSH and hence reacting to give other intermediates 
hence hindering it from forming the palladium-DNA adducts. 
 
However, palladium compound 5 showed moderate activity compared to other palladium 
complexes. It exhibited an IC50 value of 0.67 mM. The percentage apoptotic cells 
increased with increase in concentration and reached ca. 56% at 1 mM. Its variation in 
activity with compound 2, despite both being dichloropalladium complexes, is attributed 
to the ligand systems suggesting that geometric isomerisation plays an important role. 
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Compound 2 is monodentate system and could exist as trans-cis isomer in solution while 
compound 5 had a definite cis geometry imparted by the rigid ligand used. While all 
complexes with chloro ligand cis or trans to the bridging ligand have been reported to 
show good activity, it is the complexes in the trans configuration that are generally more 
active. From a mechanistic point of view, it means that compound 2 is able to form both 
intrastrand and interstrand DNA adducts while the latter having a rigid geometry i.e. cis-
conformation, could only form intrastrand DNA adducts. However in this study 
compound 2 was less active than 5 suggesting again that compound 2 is less stable in 
solution hence is susceptible to translabilization compared to 5 which is favoured by 
SARs (section 1.4) hence its activity being higher than that of the former, 2 (Figs 4.4 and 
4.6).  
 
Another observation made is the role played by the bulkiness of the ligands, i.e. pyrazole 
and 3,5-dimethylpyrazole. A comparison of the activities of compounds 3 and 4 at all 
concentrations indicated that compound 4 is more active. Palladium compounds 1 and 2 
showed similar trend with 2 being more active. However, these were thought to be 
significantly low values. 
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Figure 4.5. Comparison of the effects of ligand and the metal in the overall activity of the 
complexes. 
 
From the results obtained, it was deduced that the antitumor activity of the complexes 
increased with the increase in bulkiness of the non-leaving ligands (Fig. 4.6). The same 
observation was made by Christian et. al. when they found dichloro-2-(2-
pyridyl)benzimidazoleplatinum(II) more active than cisplatin.8 Sterically hindering bulky 
ligands are found to reduce rapid detoxification by thiol-containing molecules. There is 
also a probability that such ligands prevent translabilization and undesired displacement 
of the non-leaving ligand by other nitrogen donors.9  
 
One major undoing in our study was the inability of cisplatin to induce apoptosis in the 
CHO cells. The cells treated with cisplatin despite showing the lack of cell multiplication, 
could not stain the APOPercentageTM dye. Although cisplatin is known to induce 
apoptosis in some cancer cells, e.g. CH1 cells, as reported by other scientists among them 
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Devarajan et. al.10 and Viktorsson et al.11, surprisingly that was not the case in our 
experiments on CHO cells. From the morphological changes observed using the light 
microscopy technique, the cells stopped multiplying and looked rigid suggesting the cells 
growth inhibitory effect by the chemical. In this case we found two possible explanations 
to this result: (1) It could imply that the cells did not undergo the flip-flop mechanism, a 
phenomenon that leads to the dye passing across the cell membrane into the cytoplasm 
suggesting that the cells died via another mechanism and not apoptosis. This means the 
cell death could have been as a result of effect on spindles responsible in the homeostatic 
process of meiosis, being stiffened by the drug. Such mechanism has been reported to be 
a pathway of cell death induced by the famous natural antitumor agent Taxol.12 (2) It 
could be the fact that in respect to this cell-line, cisplatin was not a cell specific cytostatic 
drug. Its inhibition of cell division in G2-phase did not only lengthen this phase but could 
have also delayed cell death. This property of cisplatin could explain the delay/absence of 
apoptosis in comparison with the complexes tested.13 There are also published literatures 
on the inability of cisplatin to induce apoptosis on some other cancer cell types, e.g. 
L1210.14 That notwithstanding, acquisition of results on the complexes that were 
investigated was successful. The cytotoxic results obtained from the study performed 
indicated that not all the compounds exhibited a remarkable cell inhibition activity at all 
doses assayed. Generally there was an upward trend observed in the cell death caused by 
all the compounds. 
 
Compound 1 and 2 had no substantial apoptotic property detected. This is indicated by 
the quasi horizontal curve in Figure 4.6. This is similar to the results reported by Sanja et 
al.15 in which the K[Ru(eddp)Cl2] complex assayed for cytotoxicity against human breast 
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carcinoma BT-20, did not show any significant effect suggesting different ability of 
compounds to induce cell death in different cell lines vary. It is possible that these 
compounds have no significant effect on the CHO cell line used in this case but could 
have significant effect on other cell lines. But from the chemistry point of view, 
palladium complexes are known to be both thermally and kinetically unstable and thus 
undergo substitution reaction more readily than platinum complexes. Complex 1 and 2 
could have undergone hydrolysis to afford its monofunctional reactive species before it 
was induced on the cells, a factor that could explain the observation made on its activity. 
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Figure 4.6. Graphical representation of concentration-dependent effect of the compounds 
1 and 2 on CHO cells treated for 24 h respectively. No significant cell death at all 
concentrations (see text). 
 
In general platinum containing compounds were also found to be more active than those 
of palladium. Compounds 3 and 4 were found to be the more active compared to 5. 
Compound 4 is the most active. Quite apart from the screening of compounds at different 
concentrations, we were able to justify that the cell death was through apoptosis pathway 
as opposed to necrosis (lysis). This is evident from the apoptosis assay performed that 
indeed these compounds induced cell death via the programmed cell death.  
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4.4.3 Time-dependent reaction courses of the compounds on the treated cells 
Time-dependent reactions course of the compounds on test were done to investigate 
further the uptake of the drugs with time. In this case three compounds, complex 3, 4 and 
5 were used. Each compound exhibited a characteristic uptake-time curve on CHO cells, 
the common trend was an increase that reached equilibrium within 24 h. The uptake of 
the compounds was found to be slow and increasing almost linearly with time. Attempts 
to let the time-dependent experiment to run for more than 24 h were unsuccessful. This 
was attributed to prolonged incubation time thereby leading to the damage and 
subsequent blockage of the membrane functionality, as a result of extensive platination.16 
The end result was membrane damage which have could limited further analysis. A 
similar observation has been reported by Reile et al.17 
 
It is worth noting however that in this study, the compounds were tested at different 
concentration i.e. minimum concentration showing significant cell death and therefore the 
results are not comparable. Nevertheless they registered a similar trend as mentioned 
earlier. Two platinum complexes, 3 and 4 were used at concentrations 0.05 mM and 0.2 
mM respectively. Compound 5 (palladium containing) was used at concentration, 0.60 
mM. At 0.20 mM, complex 3 showed a percentage cell death of approximately 35 in 12 h 
to reach approximately 52% after 24 h. Complex 4 showed a similar pattern (at 0.05 mM) 
with percentage cell death of approximately 34 and 58 in 12 h and 24 h respectively. 
Compound 5 exhibited relatively the same time-dependent course but at a higher 
concentration of 0.60 mM. It was found to induce a percentage cell death of 
approximately 27 in 12 h to reach 40% in 24 h. Of interest was how 4 induced almost the 
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same percentage cell death as 3 and 5 but at lower concentration, a factor that shows how 
a specific metal coordinated to a given ligand with certain geometry could impart activity 
to a compound and that increase in bulkiness of the ligand leads to higher activity 
(section 4.4.3). 
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Figure 4.7. Graphical representation of time-dependent effect of the compounds on 
treated CHO cells. The treated cells (for 24 h) were stained with APOP dye and evaluated 
by FACS as indicated in text. The graphs show the effect of complexes 3 (0.20 mM), 4 
(0.05 mM) and 5 (0.60 mM) respectively. 
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4.4.4 Evaluation of mechanism of cell death by DNA and RNA content measurement  
Cell cycle analysis was a useful tool in determining the effects of the compounds being 
tested on the CHO cells. Our studies designed to investigate the relationship between the 
inhibition of DNA synthesis, cytotoxicity, and cell-cycle progression suggested that the 
complexes used inhibit DNA transcription and replication.18 We examined the effect of 
the complexes on the cell cycle progression and observed that almost all the treated cells 
did not enter the cell cycle; rather they lagged in the G1- phase. The main effect of these 
complexes was their ability to reduce cells in G1-phase accompanied with a simultaneous 
increase in cells with less than G1 DNA content (Fig. 4.9). At 24 h the treated cultures 
contained less G1- phase cells (52.15%) and 11 times more Ap-phase (apoptotic) cells 
(31.10%) compared to untreated cells which had 69.86% and 2.72% respectively (Fig. 
4.8).  
 
The cell-cycle disturbances were associated with inhibition of cell proliferation in 
agreement with results reported by Martin et al.19 in their cell-cycle disturbance studies. 
This suggests that the reduction in G1-phase cells was as a result of the accumulation of 
Ap-phase cells a fact that is attributed to induction of apoptosis by compounds in test. 
Contrary to results reported by Sorenson et al.20 in their study of cisplatin treated CHO 
cells, that the cells progressed through S phase, where DNA synthesis occurs, and were 
arrested in the G2-phase ( see Fig 2.5, chapter 2), our results indicate that the cells in G1-
phase could not encounter DNA replication (synthesis). Rather, our observation is that 
the cells were trapped in G1-phase and therefore paused their progress in the cycle and 
subsequently entered an indefinite phase, Ap-phase (31.10%). This is attributed to the 
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complex binding to DNA in G1-phase and therefore disrupting its programme of passing 
the DNA for replication in the S-phase. This then caused the cell receptors to detect the 
anomaly hence triggering apoptosis. 
 
 
Figure 4.8. Differential staining of RNA and DNA with acridine orange (section 4.2.3) 
of control. Cell cycle progression of the untreated CHO cells after 24 h. M1 = Ap-phase 
(apoptotic cells are in M1), M2 = G1-phase, M3 = S-phase, M4 = G2/M-phase. 
 
 
Dose response.001Dose response.001
0 200 400 600 800 1000
FL1-H
Dose response.001
0 200 400 600 800 1000
FL1-H
M1
M2
M3
M4
Normal cells 
 111
 
 
 
 
 
Figure 4.9. Differential staining of RNA and DNA with acridine orange (section 4.2.3) 
of treated cells. Cell cycle progression of CHO cells treated with compound 5 (0.60 mM), 
for 24 h. M1 = Ap-phase (apoptotic cells are in M1), M2 = G1-phase, M3 = S-phase, M4 
= G2/M-phase. 
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4.4.5 Induction of genomic DNA cleavage 
To further characterize the apoptotic activity of the palladium and platinum compounds, 
two complexes 3 and 5 were used to examine the ability of these compounds to induce 
DNA fragmentation in CHO cells. Using agarose gel electrophoresis, the formation of the 
nucleosomal DNA fragments by the control and drug-treated cells was investigated. The 
inter-nucleosomal DNA cleavage seen was similar to those reported by Moradell et al.2 
The undigested DNA appeared as a band of large molecular size corresponding to 
genomic DNA in control cells whereas in the treated cells there was evidence of genomic 
DNA digested into smaller fragments. Results obtained from cells treated with the 
complex 3 (platinum containing) were more pronounced than those of 5 (palladium 
containing). This was an indication of DNA double-strand cleavage occurring in the 
linker regions between nucleosomes thereby producing fragments that are multiples of 
approximately 201 base pairs (Fig. 4.10). This feature is the biochemical hallmark of 
apoptosis. 
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Figure4.10. DNA fragmentation pattern of CHO cells treated with complex 2. Lane 
identification: L1 = DNA size marker, L2 = control cells without treatment, L3 = treated 
cells, 0.05 mM, L4 = treated cells, 0.10 mM, L5 = treated cells, 0.15 mM, L6 = treated 
cells, 0.20 mM, L7 = treated cells 0.50 mM. 
 
 
 
 
 114
 
Figure4.11. DNA fragmentation pattern of CHO cells treated with complex 5. Lane 
identification: L1 = DNA size marker, L2 = control cells without treatment, L3 = treated 
cells, 0.60 mM, L4 = treated cells, 0.80 mM, L5 = treated cells, 1 mM,  
 
The DNA fragmentation visualized for complex 5 was not very clear as the bands 
appeared as smears (Fig. 4.12). It is possible that the compound could have led to an 
increase in membrane permeability resulting in the loss of small DNA fragments by the 
time of analysis and therefore could not be detected.21 This occurrence would account for 
the slight smearing of the DNA upon gel electrophoresis. It is also possible that the 
experiment was run for a longer period and consequently smears observed as opposed to 
laddering. Similar observations were reported by Bortner et al.22 and Schulze-Osthoff et 
al.23 
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4.5 Reactions of platinum(II) complex with glutathione monitored by 1H NMR 
spectroscopy 
Cis-dichloro-bis-(pyrazole)platinum(II) (Complex 3) was used as a representative 
complex in the reaction with glutathione.24 The reactions were monitored by taking a 1H 
NMR spectrum in the intervals of 1, 1.5, 3, and 18 h. For reliability, each single 
experiment was carried out at least twice, and always identical product signals and 
similar reaction proceedings were observed.  
 
Ideally the reaction of this complex with excess GSH is a typical representation of such 
reaction in vivo where the concentration of GSH in the cell is about 8-100 mM. Of 
interest was to determine the rate of reaction (ligand exchange) of compounds 1-5 with 
GSH, since GSH is one of the biomolecules that reacts with drugs in the cells leading to 
acquired resistance against the drug by the cells. This study was achieved by monitoring 
the changes in three peaks (7.93, 7.52, and 6.39 ppm) belonging to the complex upon 
interaction with GSH, as reported by Kelemu et al.3 in a similar study. This gave an in 
indication of the typical reaction in the cell. 
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Figure 4.12. 1H NMR spectra showing the reaction of complex 3 with GSH (ratio 1:2) at 
room temperature, as monitored by 1H NMR. The peaks of the complex monitored are; 
7.93, 7.52, and 6.39 ppm 
 
When compound 3 was reacted with GSH, the signals recorded at time 0 h were those of 
the complex i.e. 7.93, 7.52, 6.39 ppm (Fig.4.14). The new peaks observed at 7.59 ppm 
(doublet) and 6.24 ppm (triplet) respectively after 1h, suggested formation of a secondary 
product, indicating that there is a ligand substitution process whereby the pyrazolic ligand 
system was being displaced by the glutathione. After 1.5 h, the two new peaks were more 
pronounced. These are typical of the third and fourth protons, e and f (Fig. 4.14) of free 
pyrazole ligand emerging. Eventually at 18 h, the primary starting material (complex) 
was completely diminished. Instead, the noticeable peaks were at 7.64 ppm (d and e) and 
Complex 3 
1 h 
1.5 h 
3 h 
18 h 
7.64  
7.93 7.52
6.39 
6.30 
6 78 
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6.30 ppm (f) respectively (Fig. 4.14) corresponding to those of free pyrazole 7.64 and 
6.36 ppm. The assignment of the peaks is summarized in Table 4.2. 
 
One striking feature is the slow disappearance of the peak at 7.93 ppm (c). In the 
spectrum at 18 h it has completely disappeared. Ideally in the spectrum of free pyrazole 
there are three peaks, N-H, 4 H, with 3H (e) and 5H (d). When it is complexed, 3H (7.52 
ppm) and 5H (7.93 ppm) protons resonates at different frequencies. They exhibit different 
chemical environment a factor resulting from coordination to the metal center. Thus with 
the ligand substitution by GSH over a period of time, the peak at 7.93 ppm disappears 
leaving the peaks at 7.64 ppm (3H and 5H) and 6.30 ppm (4H) of pyrazole respectively. 
The absence of the N-H signal is attributed to the proton undergoing deuterium exchange 
in solvent. Of interest is the appearance of the peaks at ca. 8.55 and 8.32 ppm after 1h of 
reaction. At 18 h, these peaks had merged to give one broad peak at 8.43 ppm an 
indication that there was a formation of a secondary product. Alhough the observations 
made are in agreement with the theoretical principals that ligand substitution reaction 
took place, we could not speculate on the resultant product, as the attempts to isolate the 
compound for structure elucidation were unsuccessful.  
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Figure 4.13. Cis-dichloro-bis-(pyrazole)platinum(II), 3 
 
 
Table 4.2. Showing the disappearance of the complex and emerging of the ligand 
(pyrazole) substituted by GSH. 
 
Proton peaks of the complex disappearing Proton peaks of the ligand 
(pyrazole) emerging  
Time (Hours) 
c e f d f1 
0 7.93 7.52 6.40 7.60 - 
1.00 7.90 7.50 6.39 7.58 6.24 
1.50 7.92 7.50 6.39 7.58 6.24 
3.00 7.94 7.50 6.41 7.60 6.26 
18.00 - - - 7.64 6.30 
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Glutathione is known to have cysteine as one of its constituents. In this case cysteine is 
known to contain three possible coordination sites, the sulfhydryl, the amino and the 
carboxyl groups. It coordinates to platinum through the oxygen and the sulfur atoms. 
However, when cysteine is incorporated into a peptide, in this case GSH, it is sandwiched 
between glutamic acid and glycine ends. This then leads to oxygen molecule not 
available as a chelating site. It acts as a bidentate chelating ligand, coordinating to the 
platinum via the cysteinyl sulfur and nitrogen atoms (the latter, part of the peptide bond 
to glutamic acid).24 
 
Our postulate is that when the sulfur is coordinated to platinum, it will labilize the trans 
aromatic amine ligand (pyrazole) leading to its replacement by glutathione molecule 
through formation of a Pt-S bond. Several attempts to isolate the product and perform 
spectroscopic analysis in order to elucidate the possible structure were unsuccessful. 
 
4.6 Conclusions 
It is well known that one of the handicaps of cancer chemotherapy is the local toxicity 
produced by the currently used drugs, due to their accumulation in several organs and 
tissues at therapeutic doses. Apoptosis is considered to be a proper physiological pathway 
of cell death than necrosis, because lysis of the necrotic cells leads to the production of 
local side effects due to the release of toxic substances from inside the cell to the 
extracellular environment. The complexes discussed above were studied for their 
induction of apoptosis and not just their cytotoxicity. The morphological changes 
observed showed that induced cell death occurs through apoptosis. Further analysis of the 
cytotoxicity activities of these complexes by flow cytometry, indicates that they are both 
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dose and time dependent except for complexes 1 and 2 which were considered inactive. 
The highest activity of most complexes was achieved after 24 h. The measurement of 
apoptotic cells by double staining of DNA and RNA enabled the determination of the 
effects of compounds on the cell cycle of the treated CHO cells. A greater population of 
cells were found trapped in the G1-phase with time, suggesting that DNA replication is 
stopped and apoptosis take place. The observation made in the DNA fragmentation 
experiments (especially with compound 3) is an indication of the genomic DNA 
cleavage. This not only indicates apoptosis but it also shows that the complexes are able 
to bind to the DNA and as result stop DNA replication. 
 
As part of our systematic research on this type of compounds, our interest was directed to 
the substitution of platinum by its homologue palladium for the investigation of their 
potential in anticancer agents research. However platinum complexes were found to be 
more active than the palladium complexes. In addition, complexes carrying bulkier 
substituents on the pyrazole ligands were more active, suggesting that with increase in 
bulkiness the translabilization of complexes is reduced and as a result activity increased. 
In general complexes exhibiting trans disposition were found to be more active than 
those in cis configuration except for palladium complexes. One of the reasons as to why 
trans complexes could be more active than cis, apart from forming intrastrand and 
interstrand DNA adducts, is that the different accumulation can be accounted for by the 
intrinsic lower polarity of trans-geometry (idealized D2h symmetry) with respect to cis-
geometry (idealized C2v geometry). 
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The reaction of complex 3 and glutathione gave an indication of the possible reactions 
that occur in the cell in vivo. This includes the displacement of the non-leaving ligand by 
sulfur containing compounds.  
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